Executive Summary: Conditional Reimbursement and Evidence-Linked Market Access Across Europe

Europe’s healthcare systems are entering a new phase where biotech, pharmaceutical, MedTech, and digital innovations are funded not simply for being new, but for proving their real-world impact. Reimbursement now depends on Real-World Evidence (RWE), Coverage with Evidence Development (CED), and strong cost-effectiveness evaluation, moving away from the old model of “approval-first, payment-later” to flexible access routes that reward technologies showing clear clinical benefits and value to

France leads Europe’s adaptive-funding agenda. The Forfait Innovation and Article 51 Experimental Care Pathways provide national and regional coverage with mandatory evidence plans, spanning medical devices, in vitro diagnostics, digital therapeutics, and—since 2024—artificial intelligence decision-support systems. For medicines, the Accès Précoce program allows them to enter the market early while making sure they meet regulations and get paid for by Together, these create a coherent ecosystem for biotech, pharma, and MedTech innovators.

Germany combines pragmatic early access and disciplined data collection. Hospitals secure temporary funding for new procedures through NUB applications; payers and the G-BA can commission confirmatory § 137e Erprobungsstudien for conditional evidence generation; and the DiGA Fast-Track reimburses digital therapeutics nationally within three months, contingent on real-world outcomes. Parallel mechanisms exist for drugs under the AMNOG early-benefit-assessment framework.

The United Kingdom aligns rapid evaluation with mandated adoption. NICE Early Value Assessment (EVA) offers time-limited recommendations for digital and AI tools, while the MedTech Funding Mandate (MTFM) ensures nationwide implementation of NICE-approved, cost-saving technologies. For medicines, conditional access operates through the Cancer Drugs Fund (CDF) and the Innovative Licensing and Access Pathway (ILAP).

The Netherlands applies strict economic discipline through Zorginstituut Nederland (ZIN), integrating HTA with real-world data and budget-impact validation. Managed experiments and insurer-funded pilots now replace the discontinued Promising Care programme, maintaining evidence-linked conditional coverage across MedTech and biotech.

Belgium, Switzerland, and the Nordic countries rely on registry-based evaluation. Belgium’s mHealthBelgium Level 3-/3+, Switzerland’s SwissHTA/MiGeL, and the Nordic councils (TLV, SBU, NT, Findata, Kanta) transform longitudinal clinical registries into actionable proof for HTA and permanent reimbursement.

Spain and Italy are evolving from regional pilots to national frameworks. Spain’s RedETS and RRF-funded innovation procurement link local trials to national coverage, while Italy’s AGENAS HTA and Codici Temporanei allow for temporary approval of devices, tests, and targeted cancer treatments as part of a single

At the European level, the EU HTA Regulation (2025/2086) and the European Health Data Space (EHDS) are creating consistent standards for evidence, data sharing, and coding among Member States—connecting biotech, pharma, MedTech, and digital health under a single.

Across Europe, conditional reimbursement and real-world evidence generation have become the foundation of sustainable innovation. Odelle Technology partners with companies in biotech, pharmaceuticals, MedTech, and digital health to design reimbursement and evidence-generation strategies that accelerate alignment with EU HTA requirements and secure long-term funding in this rapidly evolving landscape.

France now offers the most advanced conditional reimbursement system in Europe—integrating Forfait Innovation, Article 51, Accès Précoce, PECAN, and RIHN 2.0 to fund biotech, pharma, MedTech, and AI innovations while real-world evidence is collected.

France has created a well-organised system for conditional reimbursement, allowing innovators in biotech, pharmaceuticals, medical devices, in vitro diagnostics (IVDs), and digital health to get funding while also producing the necessary evidence for long-term support.
Five complementary pathways, Forfait Innovation, Article 51, Accès Précoce (AAP), PECAN, and RIHN 2.0, form a continuous bridge between regulatory approval, real-world use, and Health Technology Assessment (HTA). Supporting programmes such as PHRC, PRME, and Ségur du numérique provide the financial and data infrastructure that sustain France’s “evidence-for-payment” model.

Forfait Innovation (FI) coverage with Evidence Development for MedTech & AI Diagnostics

Forfait Innovation is the flagship reimbursement mechanism for medical devices, diagnostics, and AI-enabled tools.

Purpose: fund national use while a prospective clinical and economic study is conducted.
Who applies: manufacturer or consortium; submission to Haute Autorité de Santé (HAS).
Timelines: Pre-submission advice → full dossier → HAS decision ≈ 6–12 months; projects run 2–4 years with interim analyses.
Evidence: endpoints agreed upfront (clinical utility, safety, cost); for system-impact technology, QALY, ICER, and budget-impact analysis (BIA) are mandatory.
Funding: The Ministry of Health and CNAM co-fund national reimbursement for each enrolled site.
The outcome of positive FI studies leads to a permanent listing in LPPR, NABM, or CCAM, along with a tariff negotiated by CEPS.
Since 2024, FI explicitly covers AI diagnostics, digital biomarkers, and connected devices, aligning with France’s AI Act implementation and Ségur interoperability standards.

Article 51: Experimental Care Pathways

Article 51 du Code de la Sécurité Sociale allows hospitals, innovators, and ARS regional networks to pilot new diagnostic, digital, or service models under temporary reimbursement.
Each project defines measurable outcomes—time-to-diagnosis, antibiotic-day reduction, avoided admissions, patient-reported outcomes (PROs)—and selects a funding architecture (bundled, capitation, or gain-sharing).

Application: via the démarches-simplifiées portal to ARS or the national committee.
Timelines: approval → first inclusion within 3–6 months; projects run 24–48 months.
Evidence: real-world outcomes + economic evaluation tracked through the CTIS.
Successful pilots migrate into “droit commun”—full integration in LPPR/CCAM or new tariff codes.

Accès Précoce (AAP) Early Access for Biotech & Pharmaceutical Innovations

The AAP scheme, which was expanded in 2021, helps connect the approval process and payment for important or rare drugs, biologics, gene and cell therapies, and advanced

The applicants are either the marketing authorisation holder or the biotech sponsor, who submit their application to HAS with input from ANSM and the Ministère de la Santé.
Timelines: evaluation ≈ 90 days; coverage continues until permanent pricing is finalised with CEPS.
Evidence: mandatory real-world data collection (registries, compassionate-use databases) + commitment to post-authorisation studies.
Funding: national health insurance reimburses the medicine at a provisional price while data accrue.
The AAP has become the standard bridge for blockbuster biologics and innovative oncology drugs, operating in parallel with Accès Compassionnel for small populations.

Companion Diagnostics (CDx) and Precision Medicine: Get Paid!

Companion IVDs used to guide targeted therapies follow a hybrid route: FI or RIHN 2.0 for the test and AAP or CEPS early access for the drug.
France’s INCa (Institut National du Cancer) and PRTS provide funding for multicentre evaluations of molecular and genomic CDx platforms, which contribute to NABM code proposals validated by HAS.
Manufacturers can ask for temporary LPPR or NABM codes, which are short-term reimbursement identifiers that help track data and ensure hospitals get paid while they gather evidence on cost-effectiveness during these evaluations.

PECAN — Digital Health Fast-Track

PECAN (Prise en Charge Anticipée Numérique) provides a one-year pilot program that pays for digital therapies, remote monitoring tools, and

Purpose: bridge the gap between proof-of-concept and full evidence submission.
Governance: joint oversight by CNAM, Délégation au Numérique en Santé (DNS), and HAS.
Funding: temporary tariff via Assurance Maladie.
The positive results from PECAN will expedite the listing process under LPPR or new digital health categories.
PECAN complements the €2 billion Ségur du numérique investment in interoperability (DMP/MSSanté) and data infrastructure, enabling large-scale real-world evaluation.

RIHN 2.0—Transitional Reimbursement for Innovative Labs and AI Acts

The Référentiel des Innovations Hors Nomenclature (RIHN) allows temporary funding for novel IVD or AI-assisted procedures pending inclusion in the NABM or LPPR.

Conditions: mandatory data capture via registry, predefined performance metrics, and HAS review after the evidence period.
Milestone 2025: HAS approved VisioCyt® Bladder, the first AI-based cytology diagnostic to receive reimbursement under RIHN 2.0.
This model formalises an AI reimbursement route: early national payment + prospective registry → HAS appraisal → permanent code once effectiveness is confirmed.

PHRC & PRME Public Research Backbone: Get paid!

The PHRC (Programme Hospitalier de Recherche Clinique) funds feasibility and safety studies for innovative interventions, while PRME (Programme de Recherche Médico-Économique) supports cost-utility and budget-impact analyses.
Together, they underpin clinical and economic evidence generation for FI, Article 51, and PECAN projects, ensuring hospital investigators have public co-funding for trials that meet HAS standards.

Timelines & Planning Matrix — Conditional Reimbursement in France (2025)

Pathway / Scheme	Eligible Technology	Submission Authority	Decision Timeline	Evidence Duration & Study Requirements	Conversion / Long-Term Outcome
Forfait Innovation (FI)	Medical devices, IVDs, connected tools, and AI-enabled diagnostics with unmet need and promising early data	HAS – Haute Autorité de Santé (Dossier “Financement Exceptionnel”)	Pre-submission meeting (recommended 3–6 mo prior); HAS decision typically within 6–12 months	2–4 years of national coverage; a prospective clinical and medico-economic study is required (QALY, ICER, BIA). Interim analyses to HAS every 12 months.	Positive results → permanent listing on LPPR/NABM/CCAM with CEPS tariff; non-confirmatory results may trigger project extension or delisting.
Article 51: Experimental Care Pathways	New care models, diagnostics integration, community screening, digital health pilots	ARS (Regional Health Agencies) with validation by CTIS – Comité Technique de l’Innovation en Santé	Expression of interest → full submission; selection cycle 3–6 months; implementation begins within 6 months post-approval	24–48 months pilot period; real-world data on clinical outcomes, patient experience, and economic savings collected across participating centres	If targets are met, the pathway is converted to “droit commun” (routine tariff under CCAM/LPPR); national replication is funded by CNAM.
Accès Précoce (AAP)	Biotech, pharmaceuticals, biologics, cell & gene therapies, ATMPs, oncology drugs	HAS (with ANSM & Ministère de la Santé**)	Assessment and decision in ≈ 90 days; can be renewed annually pending CEPS pricing	Duration linked to pricing negotiation (usually 12–24 months); mandatory RWE plan, post-authorisation studies, and safety monitoring	CEPS price negotiation → permanent inclusion in reimbursement list; RWE informs long-term pricing adjustment.
PECAN – Prise en Charge Anticipée Numérique	Digital therapeutics (DTx), remote-monitoring platforms, AI decision-support tools	CNAM / Délégation au Numérique en Santé (DNS) with HAS oversight	Fast-track review ≤ 3 months from application to funding decision	12 months derogatory reimbursement; outcomes and interoperability data required; alignment with Ségur du Numérique standards	Successful evidence dossier → LPPR code or new digital tariff; pathway may transition to Forfait Innovation or standard reimbursement.
RIHN 2.0 – Référentiel des Innovations Hors Nomenclature	Innovative laboratory acts, molecular diagnostics, AI-based image analysis	HAS / DGOS (Direction Générale de l’Offre de Soins)	Applications reviewed on rolling annual cycle; decisions are made within 6–9 months of submission	1–2 years of temporary reimbursement; mandatory data capture in national registry and predefined performance metrics	Evidence transferred to HAS for appraisal → NABM/LPPR integration or code revision; can serve as entry to FI for broad

Across all routes, France demands clear comparators, patient-centred outcomes, budget-impact transparency, and data-governance compliance (HDS/GDPR, interop FHIR).
Timelines are tightly coupled with regulatory milestones, meaning evidence generation can begin immediately post-CE mark or MA, preventing commercial dead zones.

Proper planning prevents poor performance

1. Engage early with HAS or ARS to accelerate access.
A formal pre-submission dialogue with the Haute Autorité de Santé (HAS) or Agence Régionale de Santé (ARS) can shorten evaluation timelines by up to 30%. Early engagement helps align study endpoints, comparators, and real-world data plans before dossier submission—preventing costly rounds of clarification.

2. Secure temporary reimbursement codes immediately.
Request LPPR transitoires (for devices and digital tools) or NABM provisoires (for diagnostics) as soon as pilot approval is granted. These temporary identifiers ensure that hospital activity is traceable and billable while evidence is collected, and they simplify the transition to permanent listing once evaluation is complete.

3. Build RWE pipelines that meet French data-governance standards.
All post-market evidence systems should be Ségur-compliant, supporting FHIR/HL7 interoperability and hosted by HDS-certified providers. Data collection platforms must meet GDPR standards and integrate seamlessly with national repositories such as DMP and SNDS, enabling regulators to reuse data for HTA reassessment.

4. Embed health-economic validation from the outset.
Design clinical and registry studies to generate ICER and Budget Impact Analysis (BIA) outputs consistent with French payer expectations—typically ≤ €50,000 per QALY gained and ≤ 1% of the relevant program budget. Early integration of cost-utility endpoints improves the probability of CEPS price acceptance and long-term tariff stability.

5. Anticipate full-cycle timelines from pilot to permanence.
Typical timeframes for complete evidence-to-reimbursement cycles are:

3–5 years for MedTech and digital health (Forfait Innovation, PECAN, RIHN).
For biotechnology and pharmaceuticals under Accès Précoce (AAP), the typical timeframe is 2–3 years.
4–6 years for complex, multi-site care-pathway redesigns under Article 51.
Building these durations into financial forecasts ensures adequate runway for market access and post-market evidence delivery.

Learn how biotech and pharma innovators secure reimbursement in France through AAP early access, CEPS pricing, and real-world evidence strategies.

France operates one of the most structured and transparent systems in Europe for conditional reimbursement of innovative medicines, including biologics, gene and cell therapies, immuno-oncology, and other high-impact “blockbuster” drugs.
The cornerstone of this system is Accès Précoce (AAP)—a fast, evidence-linked funding pathway that bridges the gap between regulatory authorisation and permanent CEPS reimbursement.

1. Accès Précoce (AAP): Time-Limited Reimbursement with RWE Commitments

The AAP replaced the historic Autorisation Temporaire d’Utilisation (ATU) in 2021, creating a single framework that combines compassionate access, early reimbursement, and mandatory evidence generation.
It lets biotech and pharmaceutical companies provide products to patients before they get full marketing authorisation (MA) or while waiting for regular reimbursement, as long as there is a significant expected clinical benefit (ASMR I–III) and no other treatment options available.

Eligibility: medicines addressing serious, rare, or life-threatening diseases with strong preliminary efficacy and safety data.
Submission: online dossier via HAS; co-assessment with the Agence nationale de sécurité du médicament (ANSM) and Ministère de la Santé.
Decision timeline: approximately 90 days from submission to approval; extensions renewable annually.
Evidence requirements: manufacturers must design a post-authorisation real-world data plan (RWE) capturing effectiveness, utilisation, and adverse events, and they may be required to contribute to registries or PHRC/PRME-linked economic studies.
Funding flow: reimbursed by Assurance Maladie at a provisional price, which is retrospectively adjusted after CEPS negotiation and publication in the Journal Officiel.

The AAP system has become France’s default pathway for biotechnology firms introducing gene therapies, CAR-T treatments, targeted oncology drugs, and precision-medicine biologics. Many receive reimbursement 12–18 months ahead of the full CEPS listing, allowing real-world deployment while confirmatory data accumulate.

2. CEPS Pricing and Economic Assessment

Following AAP approval and MA, pricing negotiations move to the Comité Économique des Produits de Santé (CEPS).
CEPS assesses:

ASMR (Amélioration du Service Médical Rendu): improvement in clinical benefit graded I–V; higher ASMR enables higher pricing.
SMR (Service Médical Rendu): baseline therapeutic value supporting reimbursement eligibility.
ICER and BIA evidence: consistent with French thresholds (≈ €50,000 per QALY gained, ≤ 1% national drug-budget impact).
International reference pricing (IRP): benchmarking across EU-5 economies.

CEPS outcomes are directly influenced by HAS transparency opinions, RWE data quality, and budget impact submissions.
For oncology and rare-disease therapeutics, CEPS may agree to outcome-based managed-entry contracts linking payment to real-world performance indicators (progression-free survival, remission rates, hospital-day avoidance).

3. Integration with the PHRC–PRME Research Backbone

To derisk early adoption, France funds clinical and economic evidence through public programmes.

PHRC (Programme Hospitalier de Recherche Clinique): finances investigator-initiated feasibility and comparative trials in hospital settings.
PRME (Programme de Recherche Médico-Économique): supports cost-utility and budget-impact studies feeding directly into HAS/CEPS submissions.

These allow biopharmaceutical sponsors to align R&D with reimbursement evidence standards—making early access conditional but data-driven.

4. Real-World Data and Lifecycle Management

France’s SNDS (Système National des Données de Santé) integrates claims, hospital, and mortality data for national-scale RWE studies.
AAP-approved drugs are automatically tracked within SNDS datasets, enabling CEPS and HAS to:

Evaluate treatment persistence and adherence;
Compare real-world outcomes against clinical-trial baselines;
Reassess pricing and reimbursement every five years.

This continuous feedback loop links post-market performance to future tariff renewal, embodying the EU’s vision of “paying for outcomes, not promises.”

5. Emerging Directions. From AAP to European Convergence, you get paid earlier

From 2025 onwards, France’s pharmaceutical reimbursement framework will align with the EU HTA Regulation (2025/2086) and European Health Data Space (EHDS), enabling joint clinical assessments and federated RWE sharing.
This evolution positions France as the central node for EU-wide early-access governance, offering biotech and pharmaceutical innovators a single data pipeline that supports both national CEPS pricing and EU HTA comparators.

In short, for biotech and pharmaceutical innovators looking at France, the message is clear: you must be ready for real-world performance from day one. With 366 therapies now funded under early-access schemes, including high-cost gene and cell therapies, France is doubling down on its role as a launchpad for tomorrow’s blockbusters. At the same time, price pressures and budget-cut announcements for 2026 reinforce that while the door is open, it won’t stay open without solid evidence. Innovators must prepare dossiers, registries, and economic models together— not later. In France 2025+, reimbursement has evolved from a mere box-check exercise to a full lifecycle commitment.

Netherlands Managed Experimentation + Economic Discipline (Biotech, MedTech/IVD, Digital & AI)

The Dutch system rewards controlled real-world use with strict economic validation. It mixes national levers (Zorginstituut Nederland, ZIN) with insurer-contracted pilots under the Dutch Healthcare Authority (NZa) and public research funding (ZonMw). The headline change: Promising Care (Subsidieregeling Veelbelovende Zorg) is closed to new proposals and sunsets on 1 Jan 2026; ongoing studies continue, but new care+research bundles are no longer funded via that route

1) Biotech & Pharmaceuticals Voorwaardelijke Toelating (Conditional Inclusion)

This refers to the conditional inclusion of orphan, exceptional, or conditional medicines in the Basic Health Insurance, accompanied by an evidence plan and financial arrangement. Access is granted while real-world data confirms its cost-effectivenes

Who applies/where: an MA holder submits to Zorginstituut Nederland (ZIN) using the official application form; if ZIN issues positive advice, the Minister of VWS signs a covenant with the company that sets the conditions and the financial deal.

Indicative timelines: ZIN scientific/HTA advice → policy/ministerial decision; timing depends on dossier quality and negotiations (financial arrangement + data plan). ZIN evaluates the scheme periodically (first evaluation 2022).

The evidence burden includes a prospective evidence plan, which may consist of real-world evidence (RWE) or post-authorisation studies, as well as reporting on utilisation and outcomes; it also requires economic justification that aligns with ZIN’s methods, specifically cost-effectiveness analysis (CEA) from a societal perspective and budget impact analysis (BIA). Horizon scanning is used to prepare budgets and comparators.

Payment flow: reimbursed within the basic package under the covenant; reassessment at the end of the conditional period determines permanent inclusion or exit.

Practical tips: Seek early/parallel scientific advice (EMA/EUnetHTA-style) to lock endpoints and comparators before pivotal/registry plans.

2) MedTech & IVD — Insurer-Contracted Pilots + NZa “Kleinschalige experimenten”

What it is (type): Because Promising Care is ending, most novel devices/IVDs now enter via insurer-contracted pilots and the NZa policy rule for small-scale experiments (Beleidsregel Innovatie voor kleinschalige experimenten). This allows up to 3 years of reimbursed experimentation with new ways of organising or delivering care (incl. diagnostics), after which NZa can embed the innovation in regular rules.

Who applies and where: Provider(s) + one or more zorgverzekeraars (insurers) file an experiment agreement with NZA using the official templates; parallel contracts with insurers specify tariffs and volumes.

Indicative timelines: Co-design with insurer (1–3 months typical) → NZa submission → decision; experiments run ≤3 years; if successful, NZa updates the performance/coding rules for structural funding.

Evidence burden: Real-world outcomes (diagnostic yield, time-to-diagnosis, avoided admissions), workflow impact, and budget impact at insurer level; methods may reference ZonMw frameworks for diagnostics

Payment flow: Paid via experiment tariff or within contracted bundles; after positive evaluation, innovation moves into regular reimbursement.

Practical tips: pre-align comparator, endpoints, and temporary coding/registration with the insurer; set quarterly evidence checkpoints that answer “structural inclusion” criteria.

3) Digital Health & AI — Funded via Existing Benefit Rules + NZa Digital Guide

What it is (type): The Netherlands does not have a DiGA-style national app list. Digital care (like telemonitoring, DTx, and AI decision support) is paid for using current payment codes or insurance agreements, with help from NZa’s Digital Care Funding Guide (updated 2024) that shows which care types and codes can be

Who applies/where: The provider + supplier align a business case with zorgverzekeraar(s); if the innovation changes delivery/coding, use the NZa small-scale experiment to validate outcomes and cost.

Indicative timelines: Contracting cycles are annual; experiments run ≤3 years before structural inclusion.

Evidence burden: Demonstrate clinical utility and economic value in routine care; for AI, address safety, data protection, explainability, and performance drift. National policy promotes e-health; interoperability via MedMij/HL7-FHIR is expected.

Payment flow: insurer-funded via contracted tariffs; after NZa evaluation or proven outcomes, the service becomes regularly reimbursable.

4) National Research & Policy Scaffolding — ZonMw, Health Deals, Horizonscans

ZonMw funds Good Use of Medicines (GGG) and Good Use of Diagnostics—programmes that clinch clinical utility and cost-effectiveness and feed guidance updates. Position trials/registries here to strengthen permanent inclusion cases. zonmw.nl+1
Health Deals / PPPs: structured public–private partnerships to scale precision medicine, data sharing and AI; a vehicle to derisk multi-stakeholder pilots before national rollout.
ZIN Horizon Scans: public forecasts of upcoming medicines help budget planning and comparators—useful for aligning evidence and launch timing.

Timelines & Planning Matrix Netherlands (2025)

Pathway / Scheme	Eligible Technology	Submission Body	Decision Timeline	Evidence Duration & Requirements	Conversion / Long-Term Outcome
Voorwaardelijke Toelating (Medicines)	Orphan/exceptional/conditional biotech & pharma	ZIN advice → Minister of VWS covenant	Policy + financial agreement; timing varies with dossier quality/negotiations	RWE/post-authorisation plan; outcomes & utilisation reporting; CEA (societal) + BIA	End-of-period reassessment → permanent inclusion or exit.
NZ’s Small-Scale Experiments	MedTech, IVD, digital/AI that alter delivery/coding	NZa (with insurer contracts)	Typically weeks–few months after complete application	Up to 3 years; real-world outcomes and budget impact vs usual care	The NZA incorporates the criteria into standard regulations, making the tariffs a permanent part of the system.
Insurer-Contracted Pilots	All sectors (esp. devices/diagnostics/digital)	Insurers (contracts)	Annual contracting cycle	RWD on clinical utility, pathway impact, and cost	Convert the service to routine reimbursement through either contract renewal or a change in NZa rules.
ZonMw Programmes	Diagnostics & medicines (appropriateness, utility, economics)	ZonMw	Call-based	Trial/registry evidence linked to guidelines	Strengthens ZIN decisions & guideline adoption.
Promising Care (VEZO)	Previously care+research bundles	ZIN/VWS	Closed; sunsets 1 Jan 2026	Ongoing studies continue	No new intakes; shift to NZa/insurer routes.

Discipline Delivers Access: Strategic Planning for Market Entry in the Netherlands

The Netherlands rewards precision, not improvisation. Success in securing reimbursement depends on meticulous planning, early alignment with Zorginstituut Nederland (ZIN) and Zorgverzekeraars (insurers), and a disciplined understanding of how clinical evidence, economic modelling, and societal values intersect.

Unlike larger systems that tolerate trial-and-error, the Dutch model expects innovators to arrive with data, design, and dialogue ready. Every process—whether it’s a Voorwaardelijke Toelating for a new biologic, an NZa small-scale experiment for a new diagnostic, or a digital pilot funded by insurers—works on the same idea: you get paid

To plan effectively:

Start the conversation early.
Schedule pre-submission or orientation meetings with ZIN or target insurers before designing your study. Early dialogue shortens timelines, clarifies endpoints, and prevents misalignment during covenant or contract negotiations.
Build your dossier as a single narrative.
Dutch assessors value coherence: your clinical utility, health-economic model, and societal perspective. BIA must all tell the same story of value, affordability, and equity.
Integrate evidence into delivery.
Whether through NZA pilots or insurer-funded experiments, embed RWE collection directly in clinical practice. The Netherlands has no tolerance for “data later”; evidence must flow from day one, interoperable with national systems (MedMij, FHIR, SNOMED).
Use partnerships as accelerators.
ZonMw programmes, Health Deals, and public–private collaborations with university hospitals or regional networks provide legitimacy and infrastructure to early pilots—especially for AI and precision-medicine tools.
Budget for a multi-year horizon.
The Dutch cycle from experiment to permanent listing spans 2–5 years, depending on data maturity. Financial planning should include study costs, registry build, and price renegotiation windows.

In the Netherlands, reimbursement is not a reward for innovation—it is a structured test of value under real-world conditions. Companies that treat planning as a compliance exercise fail; those that treat it as a science succeed.

The MedTech Funding Mandate (MTFM) requires the compulsory adoption of NICE-approved, cost-saving technologies across the NHS.
Early Value Assessment (EVA)—conditional recommendations for AI and digital innovations while evidence develops.
Commissioning through Evaluation (CtE) involves conducting registry-based trials for new procedures.
Innovation & Technology Tariff/Payment (ITT/ITP)—national funding for named innovations.
Cancer Drugs Fund (CDF)—an outcome-linked access model for oncology therapies.
The Digital Technology Assessment Criteria (DTAC) provides baseline evidence for procurement.
The Accelerated Access Collaborative (AAC) and the Innovate UK AI in Health Awards co-fund AI and digital pilots.

Case Study – HeartFlow FFRCT: The first imaging technology funded under MTFM, demonstrating how economic and clinical evidence can trigger nationwide reimbursement.

United Kingdom Early Evaluation → Managed Access → Mandated Adoption

The UK aligns rapid evaluation with conditional/managed access and, where value is proven, mandated national adoption. Core levers:

NICE Early Value Assessment (EVA) for fast, pragmatic decisions on AI/digital/MedTech with evidence gaps.
MedTech Funding Mandate (MTFM) to require NHS adoption of NICE-approved, cost-saving MedTech.
DTAC as the procurement baseline for all digital technologies.
Medicine routes: ILAP (accelerated licensing), NICE TA/HST, and managed access via the Cancer Drugs Fund (CDF) and Innovative Medicines Fund (IMF).
Diagnostics/CDx: NICE Diagnostics Assessment Programme (DAP) + National Genomic Test Directory (GTD) commissioning.

1) MedTech & Devices

NICE Early Value Assessment (EVA)

What: Rapid, proportionate assessment for AI/digital/MedTech where full evidence is still developing. Prioritises unmet need; issues time-limited recommendations with evidence requirements.
Who / where: NICE identifies topics; companies provide dossiers; stakeholder input at scoping.
Timelines: EVA topics progress on accelerated schedules; NICE publishes HTE/EVA guidance (e.g., AI fracture detection, digital therapies).
Conversion: Positive EVA can feed MTFM inclusion and/or full MedTech guidance.

MedTech Funding Mandate (MTFM)

What: Compulsory NHS adoption of NICE-recommended cost-saving technologies.
Eligibility: Meets three criteria (NICE-recommended; demonstrable cost saving; affordable/system-ready). The updated 2024/25 list shows an ongoing pipeline.
Effect: Removes local budget barriers; aligns with ICSs, NHS Supply Chain and Net Zero.

2) Digital Health & AI

DTAC (Digital Technology Assessment Criteria)

What: Baseline for procurement (clinical safety, data protection, technical security, interoperability, usability/accessibility).
Use: Required by providers/ICBs before buying; for developers, it signals “entry standard” to the NHS.

AI in Health & Care Award (AAC)

What: Competition funding across Phases 1–4: feasibility → clinical evaluation → real-world testing → initial NHS adoption.
Why it matters: Funds the exact studies EVA/MTFM expect; de-risks scale-up.

3) Diagnostics, IVD & Companion Diagnostics

NICE Diagnostics Assessment Programme (DAP)

What: Formal HTA for diagnostic technologies; defined process timeline from scoping to final guidance with independent assessment centre review.
Why it matters: Positive DAP guidance supports commissioning and procurement; can link to MTFM where cost-saving. NICE

Companion diagnostics & the Genomic Test Directory (GTD)

What: The National Genomic Test Directory lists genomic tests commissioned by NHS England (cancer + rare disease).
Update: The 2025/26 GTD adds/updates test codes (e.g., liquid biopsy in NSCLC).
Path: For CDx, align DAP + GTD inclusion via GMS hubs.

4) Cancer Medicines & Highly Specialised/Innovative Drugs

Cancer Drugs Fund (CDF)

What: Managed access for cancer drugs with promising value but remaining uncertainty; interim funding starts after NICE’s provisional positive stance, ahead of final guidance.
End of period: Full reappraisal; routine commissioning only if positive.

Innovative Medicines Fund (IMF)

What: £340m/year for non-cancer medicines with NICE managed access, mirroring CDF.
Status: The live list (updated Oct 2025) shows active indications and criteria. Funding begins from the NICE draft final guidance.

ILAP (MHRA)

What: Accelerates licensing via Target Development Profile and multi-agency advice (MHRA, NICE, NHS).
Relaunch: Applications for the relaunched ILAP from March 2025; MHRA update from January 2025.

NICE TA/HST

What: Technology Appraisals (TA) and Highly Specialised Technologies (HST) with statutory funding on a positive recommendation. Managed-access agreements define commercial/RWE terms.

5) The (new) 10-Year Health Plan — Opportunity SignalsUK Market Access Timelines & Planning Matrix (2025)

A unified view of UK HTA, commissioning, digital, genomics, and adoption pathways for 2025.

NICE EVA (Early Value Assessment – MedTech, AI, Digital)

Scope	Early, conditional assessment for technologies with evidence gaps (MedTech, AI, diagnostics).
Authority	NICE (Evidence Generation & Operations).
Decision Window	Rapid – typically 12–20 weeks depending on complexity.
Evidence Requirements	Focused clinical utility, early technical validity, and a clear, time-bound plan to close evidence gaps.
Conversion / Outcome	Early Value Assessment leading to conditional recommendations and structured RWE generation, with potential transition to standard NICE guidance and visibility for other adoption levers (e.g. MTFM).
Reference	NICE – Early Value Assessment programme

MedTech Funding Mandate (MTFM)

Scope	National adoption mechanism for cost-saving MedTech with positive NICE recommendations.
Authority	NHS England (MedTech Directorate).
Decision Window	Annual updates, typically aligned with the financial year (e.g. April refresh).
Evidence Requirements	Demonstrated cost savings to the NHS, robust clinical effectiveness, and implementation readiness across Integrated Care Systems (ICSs).
Conversion / Outcome	Technologies listed under MTFM must be adopted by ICSs nationally, subject to local operational constraints and timelines.
Reference	NHS England – MedTech Funding Mandate

DTAC (Digital Technology Assessment Criteria)

Scope	Baseline requirement for digital technologies procured for use in the NHS and social care (apps, platforms, AI-enabled tools, etc.).
Authority	NHS England – Transformation / Digital directorate.
Decision Window	Rolling, organisation-led assessment used during procurement and onboarding.
Evidence Requirements	Compliance across domains including clinical safety (DCB 0129), data protection, cyber security, interoperability, usability, and accessibility.
Conversion / Outcome	DTAC compliance underpins local procurement decisions and is effectively a gateway to scale within NHS settings.
Reference	NHS England – Digital Technology Assessment Criteria (DTAC)

AI in Health and Care Award (Phases 1–4)

Scope	Competitive funding to support feasibility, clinical evaluation, and real-world deployment of AI technologies.
Authority	NHS England / NIHR, formerly under the Accelerated Access Collaborative (AAC).
Decision Window	Defined by individual competition calls (Phases 1–4); cycles have historically spanned 6–12 months.
Evidence Requirements	Clear clinical use case, robust study design, health economic rationale, and a real-world evidence (RWE) generation plan aligned with NHS priorities.
Conversion / Outcome	Provides non-dilutive funding and NHS access to generate the evidence required for NICE EVA, DAP, and eventual MTFM-level adoption.
Reference	NHS AI Lab – AI in Health and Care Award

NICE DAP (Diagnostics Assessment Programme)

Scope	Formal HTA process for in vitro diagnostics and diagnostic technologies with significant system impact.
Authority	NICE – Centre for Health Technology Evaluation.
Decision Window	Typically around 9–12 months from scoping to final guidance, depending on complexity and submissions.
Evidence Requirements	Analytical and clinical validity, comparative performance, pathway modelling, and cost-effectiveness analysis (cost–utility or cost–consequence as appropriate).
Conversion / Outcome	Diagnostic guidance that informs NHS commissioning, coding and tariff decisions; can be leveraged alongside schemes such as MTFM or local innovation funds.
Reference	NICE – Diagnostics guidance and processes

NHS Genomic Medicine Service – Genomic Test Directory (GTD)

Scope	National test directory for commissioned genomic and companion diagnostic tests across England.
Authority	NHS England – Genomic Medicine Service (GMS).
Decision Window	Annual update cycle (e.g. 2025/26), with opportunities to propose new tests or modifications.
Evidence Requirements	Analytical validity, clinical validity, clinical utility, and impact on patient outcomes and NHS resources.
Conversion / Outcome	Inclusion in the GTD leads to national commissioning and delivery through the network of Genomic Laboratory Hubs (GLHs).
Reference	NHS England – NHS Genomic Test Directory

ILAP → NICE TA / HST (Innovative Licensing and Access Pathway)

Scope	End-to-end regulatory and HTA alignment pathway for transformative medicines, connecting MHRA licensing with NICE TA/HST evaluation.
Authority	MHRA, with structured engagement from NICE and other system partners.
Decision Window	ILAP entry can occur early in development; NICE TA/HST timings then follow standard appraisal processes.
Evidence Requirements	Pivotal (or near-pivotal) trial data, RWE generation plan, and readiness for commercial and access negotiations (e.g. patient access schemes, outcome-based agreements).
Conversion / Outcome	Positive NICE TA/HST normally triggers statutory funding obligations within 90 days in England.
Reference	MHRA – Innovative Licensing and Access Pathway (ILAP)

Cancer Drugs Fund (CDF) & Innovative Medicines Fund (IMF)

Scope	Cancer Drugs Fund (CDF): managed access for promising cancer medicines with clinical uncertainty. Innovative Medicines Fund (IMF): similar model for non-cancer high-cost innovative medicines.
Authority	NHS England in partnership with NICE.
Decision Window	Entry typically follows draft NICE guidance where uncertainty is considered addressable via structured RWE collection.
Evidence Requirements	Managed-access agreement, clear RWE and data collection plan, and agreement on how uncertainty will be resolved by the time of re-appraisal.
Conversion / Outcome	At re-appraisal, products either transition to routine commissioning, remain under managed access (exceptional), or exit funding if cost-effectiveness is not demonstrated.
Reference	NHS England – Cancer Drugs Fund NHS England – Innovative Medicines Fund

One-Page Summary Table (Cross-Pathway View)

Pathway / Scheme	Scope	Authority	Decision Window	Evidence Requirements	Primary Outcome
NICE EVA	Early value assessment for MedTech, AI, and diagnostics with evidence gaps.	NICE	~12–20 weeks	Clinical utility, technical performance, and structured evidence gap plan.	Conditional recommendations and RWE plan, potential step towards full guidance.
MTFM	National adoption mechanism for cost-saving MedTech with NICE guidance.	NHS England	Annual update cycle	Demonstrated cost savings and implementation readiness.	ICS-level adoption required nationally.
DTAC	Baseline procurement standard for digital technologies.	NHS England	Rolling, local	Clinical safety, data protection, cyber security, interoperability, usability.	Enables procurement and scale within NHS organisations.
AI Award	Funding stream for AI feasibility, clinical trials, and RWE.	NHS England / NIHR	Competition-dependent	Study design, NHS relevance, and RWE plan.	Generates evidence to support EVA, DAP, and MTFM readiness.
NICE DAP	Formal diagnostic HTA for IVDs and other tests.	NICE	~9–12 months	Analytical & clinical validity, comparator evidence, economic modelling.	NICE diagnostic guidance informing commissioning & coding.
GTD (NHS GMS)	National genomic and companion diagnostic test directory.	NHS England (GMS)	Annual cycle	Analytical & clinical validity, utility, health system impact.	Nationally commissioned testing via GLHs.
ILAP → TA/HST	Joined-up regulatory/HTA pathway for innovative medicines.	MHRA + NICE	Pathway-dependent	Pivotal evidence package and RWE strategy.	Positive TA/HST → statutory funding obligations.
CDF / IMF	Managed access for cancer and non-cancer innovative medicines.	NHS England + NICE	Linked to NICE draft guidance	Managed-access contracts and RWE obligations.	Re-appraisal → routine commissioning or exit.

Plan. Prove. Procure. Strategic Planning for the UK

Start with the end in mind (MTFM or TA/HST).
Design your EVA/DAP dossier or ILAP plan to hit the criteria that trigger MTFM (cost saving, implementable) or a positive TA/HST with a manageable budget impact.
Make DTAC your default.
If digital or AI is involved, DTAC compliance is non-negotiable; it smooths ICS procurement and shortens local due diligence.
Fund your evidence the smart way.
Use the AI Award to pay for feasibility/clinical/RWE milestones that EVA/MTFM will later rely on. For diagnostics, align with NICE DAP timelines; for CDx, plan toward GTD inclusion.
Choose the right medicine path.
For pipeline drugs, ILAP (re-launched 2025) + NICE managed access (CDF/IMF) creates early funded use while uncertainties are answered, then statutory funding after a positive reappraisal.
Exploit the 10-Year Plan tailwinds.
Target use-cases The plan prioritises AI safety, community care, and genomics and proves productivity and equity, along with outcomes, to win national support.

Germany: Pragmatic Early Access & Real-World Data Discipline

Germany blends rapid, real-world use with hard evidence requirements. Hospitals can start with NUB (budget top-ups before DRG integration), innovators can be routed into formal CED trials (§137e), digital therapeutics scale via DiGA Fast-Track, and pharma faces AMNOG from day one. Underpinning this are coding rails (OPS/EBM), Innovationsfonds research capital, KHZG/KHZF digital infrastructure, and §64e SGB V genome-sequencing model projects for oncology/rare disease.

1) Inpatient MedTech/IVD — NUB → DRG integration

What it is: Annual hospital mechanism (NUB – Neue Untersuchungs- und Behandlungsmethoden) to obtain supplemental payment for novel procedures/devices not yet fully reflected in DRGs. Hospitals file each year; the deadline is 31 October via the InEK portal. Positive NUB status enables case-by-case budget negotiations with payers while evidence is generated.

Who applies / where: Hospitals (often with manufacturer support) → InEK data portal.

Timelines: The submission window opens in early September, submissions are due by October 31, and negotiations with payers occur after the InEK status is published.

The evidence burden includes clinical utility in real-world applications, resource utilisation, the comparator pathway, and cost impact.

Conversion: When evidence and volumes mature, procedures/devices are mapped into DRG via OPS coding updates and DRG cost studies. bfarm.de+1

2) Coverage with Evidence Development §137e Erprobungsstudien (G-BA)

What it is: Formal coverage-with-evidence development (CED). The G-BA commissions Erprobungsstudien when evidence is promising but uncertain; statutory insurers fund use during the trial under a predefined protocol.

Who applies / where: The process is triggered at G-BA, where stakeholders can propose it; the study design is often conducted in collaboration with external scientific bodies such as IQWiG and IQTIG.

Timelines include the decision to initiate a trial, followed by protocol development and multicentre real-world data/randomised controlled trials (RWD/RCT); the typical overall duration is 2 to 4 years, with a reappraisal upon completion that determines routine coverage.

Evidence burden: Comparative effectiveness, safety, utilisation; often includes budget impact and care-pathway modelling.

Conversion: Positive result → G-BA positive coverage and coding adjustments (OPS/EBM).

3) Digital & AI — DiGA Fast-Track (and DiPA for nursing)

What it is: BfArM “app on prescription” fast-track for digital therapeutics/AI (class I/IIa software). Maximum 3-month review; listing can be permanent (with full evidence) or provisional (12 months) while you run RWE studies to prove a positive healthcare effect. Prescribable by physicians/psychotherapists; reimbursed by SHI.

Who applies / where: Manufacturer → BfArM DiGA portal.

Timelines: Clock-tight ≤3 months; provisional listing 12 months (extendable once) to complete RWE.

Evidence burden: Clinical benefit or structural/process improvement measurable in care; privacy, interoperability, and usability prerequisites.

Conversion: Positive RWE → permanent DiGA listing (national reimbursement code & price). (Example category: Selfapy became permanently listed after validated outcomes.)

(Note: A parallel track exists for DiPA in nursing care.)

4) Outpatient adoption & coding — EBM (community) and OPS (hospital)

OPS (Operationen- und Prozedurenschlüssel) encodes inpatient procedures; annual updates (e.g., 2025 OPS). Your hospital’s use and cost tracing depend on correct OPS mapping.
EBM is the ambulatory physicians’ fee schedule. To move diagnostics/services into community reimbursement, sponsors work with associations and G-BA to secure EBM codes & point values after evidence is accepted.

Draft/temporary use: During evaluations, draft OPS/EBM arrangements and selective contracts help capture activity and budget before structural inclusion.

5) Pharma & “blockbuster” drugs AMNOG (early benefit assessment)

What it is: From launch, every new active substance undergoes AMNOG: G-BA/IQWiG assesses the added benefit vs. the appropriate comparator (§35a SGB V). The outcome (e.g., “considerable/minor/no added benefit”) sets the stage for price negotiation with the SHI umbrella. The process completes within 12–15 months from marketing.

Who applies / where: MA holder → G-BA dossier (clinical + economic arguments).

Timelines: Dossier at launch; benefit decision ≤1 year; price negotiation follows.

The evidence burden consists of a preference for pivotal randomised controlled trials (RCTs), while real-world evidence (RWE) is increasingly utilised for specific subgroups, utilisation, and safety assessments; additionally, health-economic and budget impact analyses inform negotiations.

Conversion: Positive added benefit → higher reimbursed price; reassess with indicated expansions.

6) Companion diagnostics & IVD

Inpatient: Introduce via NUB + OPS coding; if evidence gaps exist, propose §137e CED.
Outpatient: Pursue EBM inclusion via G-BA once clinical utility is established; for genomic oncology/rare disease, align with §64e SGB V genome-sequencing model projects and regional networks (genomDE/ZPM), which couple clinical & genomic data into a shared infrastructure for HTA and commissioning.

7) National research & digital rails

Innovationsfonds (§92a SGB V) — €200m/year for new care models and health-services research (RWD, integrated care, digital pilots). Use this to co-fund multicentre evidence that G-BA and payers accept.

KHZG / KHZF (Hospital Future Act/Fund) — €4 bn for hospital digitalisation (EHR, patient portals, meds mgmt, IT security). Strengthens data capture/interoperability that DiGA/§137e/NUB projects rely on.

§64e SGB V genome sequencing model — national model projects in oncology/rare disease that pair sequencing with clinical outcomes; builds a durable evidence backbone for CDx/IVD coverage decisions.

Timelines & Planning Matrix — Germany (2025)

Pathway / Scheme	Scope	Authority	Decision Window	Evidence Requirements	Conversion / Outcome
NUB (hospital top-up)	Inpatient MedTech/IVD	InEK (hospital-led)	Annual; apply by 31 Oct	Real-world use, costs, comparators	DRG/OPS integration after evidence & cost studies.
§137e Erprobungsstudien (CED)	Devices/diagnostics with promising but uncertain evidence	G-BA (with IQWiG/IQTIG)	Decision → study start varies; typical cycle 2–4 yrs	Comparative effectiveness, utilisation, BIA	The G-BA reappraisal process determines whether to continue with routine coverage or to stop.
DiGA Fast-Track	Digital therapeutics/AI (class I/IIa software)	BfArM	≤3 months	Full or provisional evidence; privacy/interop	The listing will be provisional for a period of 12 months and will become permanent if the results are positive.
AMNOG (pharma)	New active substances	G-BA / IQWiG	≤12–15 months to price	Added-benefit assessment vs comparator; RWE support	The price will be negotiated, and we will reassess with
EBM inclusion (community)	Outpatient diagnostics/services	G-BA / KBV	Multi-stage, evidence-driven	Clinical utility & cost impact	Structural ambulatory reimbursement.
Innovationsfonds §92a	New care models, services research	G-BA/Innovationsausschuss	Call-based	Multicentre RWD; economic endpoints	Paths to structural funding & rule changes.
KHZG/KHZF	Hospital digital infra	BMUV/BMG-led programmes	Funding windows	Interop, IT security, portals, meds mgmt	Enables RWD capture for the above pathways.
§64e SGB V (genome seq)	Oncology/rare-disease sequencing + outcomes	GKV-SV / partner UHs	Programme-based	Linked clinical-genomic RWD	Inputs to G-BA/CDx coverage; networked commissioning. gkv-spitzenverband.de

Plan. Prove. Pay. Strategic Planning for Germany

For pharma: Treat AMNOG as the product’s “Day 1” business case—line up RCT + RWE, comparator fit, and price strategy to land an added-benefit outcome.

Pick the entry rail: inpatient devices/IVDs start with NUB; digital starts with DiGA; high-uncertainty tech aims for §137e to lock a funded CED.

Code early: Secure/validate OPS mapping for hospitals and prepare the route to EBM for ambulatory use.

Fund the evidence: Use the Innovations Funds to co-finance multi-center RWD; align outcomes with G-BA decision questions.

Wire the data: Leverage KHZG/KHZF digital upgrades so registries are interoperable and audit-ready.

For oncology/CDx: Link to §64e genome-sequencing projects to couple test usage with treatment outcomes for faster EBM/coverage decisions.

Belgium Pyramid-First, Registry-Ready

Belgium has built one of Europe’s most disciplined, transparent, and data-orientated frameworks for introducing innovative medical technologies, digital health tools, and biopharmaceuticals. Its reimbursement system—administered by NIHDI/RIZIV—is deeply integrated with health technology assessment (HTA) through the KCE (Belgian Health Care Knowledge Centre) and prioritises real-world evidence (RWE) and socio-economic value.

In practice, every new technology—whether it’s digital, diagnostic, a device, or a drug—follows a clear process that connects its clinical effectiveness, ability to work with other

1. Digital Health & AI — The mHealthBelgium “Validation Pyramid”

What it is

The mHealthBelgium programme in Belgium, which is a joint initiative by NIHDI/RIZIV, FAMHP (Federal Agency for Medicines and Health Products), and eHealth, utilises a three-level pyramid to classify and validate digital health and AI solutions:

Level	Focus	Outcome
M1	Legal compliance, CE marking, cybersecurity, basic quality	Public registration and eligibility for pilot projects
M2	Interoperability, connectivity with eHealth and hospital systems	Technical validation: prerequisite for scale-up
M3	Demonstrated clinical benefit and socio-economic impact	Enables temporary or permanent reimbursement under NIHDI/RIZIV supervision

At M3, solutions may receive temporary funding linked to evidence generation—usually a 12–24-month period overseen by KCE to collect real-world effectiveness, cost, and workflow data.
After this phase, a positive evaluation can lead to a national reimbursement convention, full tariff integration, or structured pilot renewal.

Who applies

Digital solution developers submit via the mHealthBelgium portal (mhealthbelgium.be). The process includes technical and ethical review by FAMHP and NIHDI/RIZIV.

Timelines

M1 → M2: Rolling acceptance; typically 2–3 months with supporting documentation.
M3: The evaluation window lasts 6 to 12 months and includes the development of an evidence plan and discussions with payers.
RWE phase: 12–24 months, followed by a final KCE/NIHDI review.

Evidence expectations

Evidence should demonstrate clinical effectiveness, patient engagement, or system efficiency gains.
The Budget Impact Analysis (BIA) and Cost-Utility Analysis (CUA) are conducted using Belgian thresholds.
The eHealth platform, Vitalink, ensures full interoperability while also adhering to GDPR and ISO/IEC 27001 for data security.

Conversion

A positive KCE or NIHDI assessment converts the M3 pilot into:

Permanent reimbursement listing, or
Convention-based funding, renewed every 3–5 years depending on evidence strength.

2. MedTech and IVD: The Implants and Invasive Devices List

What it is

Belgium’s List of Implants and Invasive Medical Devices (Liste des Implants et Dispositifs Médicaux Invasifs) is the official reference for reimbursable medical devices. It includes prostheses, surgical implants, IVD kits, and high-value instruments, updated several times a year by NIHDI/RIZIV.

Inclusion means that the device is assigned a national reimbursement code, applicable conditions (clinical indication, centre authorisation), and a tariff funded by statutory health insurance.

Who applies

Manufacturers or distributors submit dossiers to NIHDI/RIZIV’s Medical Devices and Implants Division, often in collaboration with clinical experts or hospitals. Devices must also be notified in the FAMHP database, a legal prerequisite for reimbursement.

Timelines

Calls for submissions are quarterly.
Review and decision periods typically last 6–9 months depending on dossier completeness and class of device.

Evidence expectations

Clinical utility and safety data are gathered from CE marking and post-market studies.
The evidence will be compared to that of existing reimbursed devices.
The economic justification should demonstrate either cost neutrality or potential cost savings.

Conversion

Approved devices appear in the NIHDI official list, with tariffs and conditions published in the Belgian Official Gazette. Updates are recurrent, reflecting device upgrades, registry data, or new clinical evidence.

3. Pharmaceuticals & Biotechnology—AmNOG-Style Pragmatism, Belgian Precision

What it is

Drug reimbursement is managed by INAMI/RIZIV and scientifically reviewed by the CTG (Commission de Remboursement des Médicaments) and the CRM (Comité de Remboursement des Médicaments).
Belgium employs a rigorous HTA and pricing model inspired by both NICE and IQWiG, with cost-effectiveness thresholds applied flexibly based on therapeutic area.

Three main routes exist:

Standard Reimbursement: For medicines with complete clinical and economic evidence.
Convention Agreements: Time-limited, risk-sharing contracts used for high-cost, high-uncertainty drugs (e.g., oncology, orphan).
Pilot Constrained Access: For early use in rare or innovative therapies, often with registry-based outcome collection.

Evidence expectations

Cost-Effectiveness Analysis (CEA) and Budget Impact Analysis (BIA) are required by NIHDI.
Disease registries, such as those in oncology and multiple sclerosis, provide real-world evidence.
Comparator-based incremental benefit demonstration.

Timelines

Initial NIHDI review: 90–120 days.
Final decision and listing: 6–12 months from submission.
Convention renewal or re-evaluation: Every 3 years, based on outcomes and pricing evolution.

Conversion

Successful applications lead to inclusion in the Reimbursement List for Pharmaceuticals, published quarterly.
For high-impact drugs, risk-sharing conventions tie reimbursement to outcome-based metrics and real-world utilisation reports.

4. Coding, Registries & Evidence Systems

Healthdata.be — National platform connecting hospitals and public databases for real-world evidence and outcomes tracking.
FAMHP — Ensures regulatory alignment for devices, diagnostics, and pharmaceuticals.
KCE is an independent organisation that looks at the clinical, ethical, and economic aspects of healthcare and gives advice that greatly
RWE Integration: National registries in oncology, orthopaedics, and cardiology are often mandated as part of reimbursement agreements.

Timelines & Planning Matrix — Belgium (2025)

Pathway / Scheme	Target Technology	Authority	Decision Window	Evidence Duration	Conversion / Outcome
mHealthBelgium M1–M3	Digital health / AI	NIHDI/RIZIV + KCE + FAMHP	Rolling → 6–12 mo	12–24 mo RWE	M3 → reimbursement or convention
Implants & Invasive Devices List	MedTech / IVD	NIHDI/RIZIV + FAMHP	Quarterly	Continuous	Listing in NIHDI device list with tariff
Pharma/Biotech	Drugs / biologics	INAMI/RIZIV + CTG/CRM	6–12 mo	Ongoing registry RWE	Inclusion in reimbursement list or convention
KCE / Registry HTA	Cross-sector	KCE + NIHDI	Ad hoc	Continuous	Evidence informs updates, renewal, and pricing

Precision Pays — Strategic Planning for Belgium

Map your entry lane early: Decide if your product aligns with mHealthBelgium, the Implants List, or NIHDI/CTG pharma evaluation. Parallel submissions save months.
Pre-engage KCE: Early dialogue clarifies the required evidence (clinical utility, cost thresholds, RWE design).
Integrate registries: Plan RWE collection through healthdata.be or disease-specific registries to satisfy convention renewal.
Synchronise regulatory and reimbursement; submit FAMHP notifications in tandem with NIHDI dossiers to prevent administrative gaps.
Budget for iteration: Belgium favours renewal-based funding—3–5-year reimbursement cycles tied to periodic evidence updates.

In Belgium, precision, not speed, determines access.
Those who design for evidence maturity, registry traceability, and economic transparency move fastest through the pyramid—from pilot to permanent reimbursement.

Switzerland Lists, Lists, and Structured HTA

Switzerland runs on positive lists and tariff systems anchored in the Federal Office of Public Health (FOPH/BAG). Basic (compulsory) insurance under LAMal/KVG pays for what is included on the list; anything extra usually falls under private insurance, which is managed by the Insurance Contract Act ( Knowing which list or tariff you’re targeting (and when) is 90% of the strategy.

1) Devices & Appliances — MiGeL/LiMA (positive list)

What it is. The MiGeL/LiMA list defines aids & appliances reimbursed by compulsory insurance (e.g., ostomy, diabetes aids, and orthopaedic supports). Entry requires proof of effectiveness, appropriateness, and cost-effectiveness; decisions and tariffs are published by FOPH. Inclusion = national coverage under LAMal.

Who applies / where. Manufacturer or professional body → FOPH/BAG dossier for MiGeL inclusion or update.

Timelines. Rolling/call-based; changes appear in periodic FOPH updates (expect several months from complete dossier to listing).

Evidence burden. Clinical performance vs. standard of care; usability; cost comparison versus currently listed items; anticipated volumes/budget impact. Tip: Preload real-world utilisation data from Swiss centres to support tariff settings.

Conversion. Successful listing → MiGeL code + tariff; 3-year re-reviews may adjust tariff/indications.

2) Laboratory / IVD — Analysenliste (AL) under KLV

What it is. The Analysenliste (AL) is the positive list of reimbursable lab tests (with codes/tariffs). Only AL-listed analyses are covered by compulsory insurance. Additions follow an evidence review of analytical validity, clinical utility, and economics (e.g., DPYD pharmacogenetic testing admitted on clinical & cost grounds).

Who applies / wwhere?plications via FOPH (Commission for Analyses, Aids & Appliances).

Timelines. Periodic AL updates; planning for 6–12+ months from dossier to listing depending on complexity/workload.

Evidence burden. Diagnostic accuracy, clinical utility (change in management/outcomes), and cost-effectiveness vs. current testing pathways; volumes to inform tariff setting.

Conversion: AL code + tariff published; subsequent re-reviews can alter tariff/scope.

3) Pharma & Biotech Specialities List (SL/LS) + Art. 71 KVV bridge

What it is. After Swissmedic marketing authorisation, outpatient medicines seek inclusion on the Specialities List (SL/LS) to be reimbursed under LAMal. FOPH assesses effectiveness, appropriateness, and cost-effectiveness; prices are re-reviewed every 3 years. For high-need situations where a drug is not on SL, Art. 71a–d KVV allows individual case reimbursement (insurer approval) when no alternative exists and high benefit is expected. Recent policy changes increased transparency by publishing SL applications and review bases.

Who applies, and where is the application process? , MA holder → FOPH for SL inclusion; Art. 71 requests are managed case-by-case with the patient’s insurer under FOPH rules.

Timelines. The SL assessment and pricing negotiation usually take from several months to about one year, depending on the quality of the dossier and the therapeutic area; a triennial re-pricing occurs thereafter. Art. 71 decisions occur faster but do not create general coverage.

Evidence burden. Pivotal randomised controlled trials (RCTs) demonstrating added benefit, assessments of budget impact compared to reference countries, and commitments to outcomes for high-cost therapies are all common practices. Swissmedic–FOPH coordination can speed parallel authorisation/reimbursement planning.

Conversion. SL inclusion → national outpatient reimbursement; inpatient use priced via SwissDRG with supplements for select high-cost drugs. Art. 71 can bridge access until the SL decision but remains patient-specific. ,

4) Tariffs & Coding — SwissDRG/CHOP, TARMED → TARDOC (2026)

Inpatient acute care: SwissDRG (flat-rate per case) groups activity; clinical procedures are coded with CHOP (Swiss procedure classification). Proper CHOP mapping is essential for hospital adoption, cost tracing, and supplement payments while evidence matures.
Inpatient psychiatry: TARPSY DRG system.
Outpatient physician services: TARMED today, moving to TARDOC from January 2026—plan fee schedule impacts for clinics using novel diagnostics/services.

5) Digital & AI How they’re paid (no single “DiGA-style” list)

Switzerland does not operate a national app formulary like DiGA. Digital/AI solutions are typically funded by:

Embedding within existing AL, MiGeL, SwissDRG/CHOP, or TARMED/TARDOC services (e.g., AI-assisted reads, remote monitoring billed under existing acts); and/or
Regional contracts with insurers and providers may sometimes allow supplementary insurance to cover non-LAMal benefits, such as premium service models; however, this coverage cannot replace SL/AL/MiGeL when basic coverage is necessary. EDA+1

Evidence expectations. Demonstrate added value within the existing tariffed act (accuracy, speed, and avoided admissions) and provide a costed workflow showing net savings or budget neutrality.

6) Private (Supplementary) Insurance — Where it helps (and where it doesn’t)

Supplementary insurance (LCA/VVG) can fund amenities and extras (e.g., private ward, additional lenses, some wellness/comfort add-ons). It’s optional, medically underwritten, and cannot override the LAMal rule that basic benefits must be on SL/AL/MiGeL (or tariff-funded) to be reimbursed from mandatory insurance. FINMA licenses and supervises these insurers. For launch strategy, use supplementary cover for value-added service layers—not as a substitute for SL/AL/MiGeL.

Timelines & Planning Matrix — Switzerland (2025)

Pathway / List	Scope	Authority	Decision Window	Evidence	Conversion / Outcome
MiGeL/LiMA	Aids & appliances (devices)	FOPH	Rolling / periodic	Effectiveness, appropriateness, cost-effectiveness	MiGeL code + tariff; 3-year re-reviews.
Analysenliste (AL)	Lab/IVD tests	FOPH	Periodic	Analytic validity, clinical utility, economics	AL code + tariff; periodic updates.
SL / LS	Outpatient medicines	FOPH (post-Swissmedic)	Months–~1 year	Added benefit, cost-effectiveness & BI	National reimbursement; triennial price review.
Art. 71 KVV	Individual-case drug cover	Insurer (per FOPH rules)	Case-by-case (fast)	High need, no alternative, expected benefit	Patient-specific funding; no general listing.
SwissDRG/CHOP	Inpatient	SwissDRG Assoc./FOPH	Annual updates	Procedure coding + cost data	DRG payment; supplements for select high-cost items.
TARMED → TARDOC	Outpatient services	Tariff partners/FOPH	TARDOC live Jan 2026	Service descriptors + time/resource use	New outpatient tariff logic for clinics.

Precision Gets Paid: Strategic Planning for Switzerland

Pick your list early. Decide MiGeL vs. AL vs. SL from day one and build your dossier to those tests (effectiveness/utility/economics). If inpatient-first, secure CHOP coding and a SwissDRG narrative for supplements. EDA+1
Exploit parallelism. Run Swissmedic→SL planning in parallel; if timing is tight for high-need patients, prep Art. 71 KVV guidance for centres while the SL file is under review.
Design for re-review. Model 3-year price/tariff checks into your economics; agree on outcomes that support tariff protection at review.
Tariff-aware digital. For AI/digital, map exact acts and tariff positions (AL code, MiGeL item, TARMED→TARDOC chapter). If it doesn’t map, it doesn’t scale.
Use supplementary wisely. Position supplementary insurance for premium service layers (private ward, add-on lenses), not as a replacement for LAMal coverage.

Sweden National HTA Spine, Regional Execution

Sweden runs a national evidence core with regional delivery and budgets. Three national bodies shape decisions:

TLV (Tandvårds- och läkemedelsförmånsverket) – health-economic assessment and reimbursement decisions for outpatient medicines and commissioned evaluations for medical technologies.
NT-rådet (the National Council for New Therapies) – national recommendations for hospital medicines (managed introduction).
SBU (Swedish Agency for Health Technology Assessment and Assessment of Social Services) – rigorous evidence syntheses that feed TLV/NT-rådet and regional policy.

Care is commissioned by 21 regions, which procure devices, contract digital services, and implement NT-rådet/TLV guidance through a long-standing “ordnat införande” (managed introduction) framework. The RWE relies on national quality registries for conditional/gradual rollout and reappraisal.

1) Digital Health & AI

What it is (how it’s paid):
Sweden has no DiGA-style national app list. Digital tools (telemonitoring, virtual wards, decision support/AI, and DTx) are paid through regional procurement and contracting, often as service bundles. Many regions require a TLV health-economic assessment (commissioned by the national MTP-rådet, see below) to support a harmonised national recommendation before scale-up.

Who applies / where:
Vendors engage in intra/regional procurement frameworks and the target region(s). For national alignment, the innovation is channelled via MTP-rådet (National Council for Medical Technologies), which can commission TLV to produce a health-economic evaluation; the assessment then informs national recommendations to regions.

Timelines (typical):

Early dialogue with target region(s): 1–3 months to define use case, data, and deployment.
MTP-rådet scoping → TLV evaluation (if commissioned): ~6–12 months depending on data maturity.
Regional adoption decisions follow the national recommendation cycle (quarterly/biannual updates are common).

Evidence burden:

Demonstrate clinical utility (time-to-diagnosis, avoided admissions, LOS reduction, PROMS/PREMS).
The budget impact should be assessed at the regional level, along with the valuation of productivity and equity impacts.
Interoperability with national rails (Inera, 1177, NPÖ) and information security meeting regional requirements (ISO 27001/27701 patterns; GDPR/Patient Data Act).
Post-market RWE via national quality registries or regional data lakes for reassessment.

Conversion:
Positive national recommendation → coordinated regional procurement, with registry-based outcome obligations and periodic re-reviews.

2) MedTech & IVD (inpatient + outpatient)

National route (for alignment): MTP-rådet → TLV (commissioned)

What: The MTP Council (Nationell samverkansmodell) can prioritise a device/IVD for a TLV health-economic assessment, producing a national recommendation to regions.
Why it matters: Prevents 21-region drift; anchors the decision in comparative effectiveness and cost per outcome.

Hospital/inpatient adoption:

Regions adopt via DRG-based payments (Swedish/NordDRG variant) and KVÅ procedure codes for activity logging. Hospitals run controlled introductions with registry capture.

Outpatient/primary care adoption:

Regions contract suppliers and set tariffs. For certain IVDs, national procurement catalogues and KVÅ codes are used; if high impact, MTP-rådet/TLV is engaged for a national stance.

Timelines:

Regional pilot & procurement: 3–9 months (depending on risk class, IT integration).
MTP-rådet/TLV cycle: 6–12 months from scoping to recommendation.

Evidence burden:

Comparative effectiveness against standard of care;
Cost-effectiveness (cost per QALY or cost per key outcome);
Implementation feasibility (workflow, staff time, training);
Registry plan for RWE.

Conversion:
National recommendation + registry follow-up → routine use across regions, with updates after RWE milestones.

3) Pharmaceuticals & Biotech (incl. “blockbusters”)

Outpatient medicines – TLV reimbursement (Pharmaceutical Benefits Scheme):

What: The MA holder submits to TLV for inclusion in the pharmaceutical benefits; TLV decides list status and price based on cost-effectiveness (CEA/QALY) and budget impact.
Timelines: Typically, ≤180 days are targeted under the EU Transparency Directive; complex cases can extend.
Conversion: Positive decision → national outpatient reimbursement; regions pay per prescription.

Hospital medicines – NT-rådet (managed introduction):

What: NT-rådet issues national recommendations for new hospital drugs (oncology, ATMPs, immunology). Contracts/price-volume agreements are often negotiated centrally (e.g., via SKR/Amgros-style collaborations where applicable).
Evidence: Robust RCTs + Swedish RWE plan (registry endpoints, PROMs).
Conversion: Regions implement recommendations in a coordinated way, with follow-up through registries.

Lifecycle & reassessment:

TLV and NT-rådet expect post-launch evidence; price/positioning can be revisited when real-world outcomes, utilisation, and comparators evolve.

4) Companion Diagnostics (CDx) & Advanced Genomics

Commissioning: CDx is typically co-introduced with the medicine through NT-rådet’s managed introduction, using National Genomic and Cancer Registries to track linkages between testing and outcomes.
Procurement & coding: Regions procure assays/platforms; activity is logged via KVÅ; reimbursement flows through hospital/clinic budgets.
Evidence: Treatment outcomes (response rates, survival, and avoided toxicity/cost) are tied to analytical validity and clinical utility.

5) Coding, Data & Interoperability Rails

KVÅ – Sweden’s Classification of Health Care Measures for procedure/act coding (essential for logging device/IVD use and digital services).
NordDRG (Swedish version) – DRG-based payment in inpatient care.
National Quality Registries—>100 disease-specific registries capturing outcomes and resource use (the backbone for CED-style adoption and policy reappraisal).
Inera / 1177 / NPÖ – national e-health infrastructure and patient portal; secure messaging, data exchange across regions.
Governance: GDPR + Patient Data Act; regional information-security baselines align with ISO frameworks.

Timeline and Planning Matrix Sweden (2025)

Pathway / Scheme	Scope	Who Applies / Where	Decision Window	Evidence Requirements	Conversion / Outcome
Digital/AI (regional + national alignment)	Telemonitoring, AI CDSS, DTx	Vendor → target Region(s); for national stance, MTP-rådet may commission TLV	Regional pilot 3–9 mo; TLV eval 6–12 mo	Clinical utility, budget impact, security/interop; registry-based RWE	National recommendation → coordinated regional procurement; periodic re-review
MedTech/IVD (inpatient)	Devices/tests in hospitals	Hospitals/Region procurement; MTP-rådet → TLV when needed	3–9 mo (regional); 6–12 mo (national eval)	Comparative effectiveness, cost-effectiveness, implementation	Routine use via DRG + KVÅ; registry follow-up
MedTech/IVD (outpatient)	Primary/community diagnostics	Regional procurement; national eval if high impact	3–9 mo	Utility, cost per outcome, and data capture plan	Regional tariffing; option to escalate to national alignment
Outpatient medicines (TLV)	Retail pharmacy drugs	MA holder → TLV	Target ≤180 days	CEA/QALY + BIA; Swedish comparators	Inclusion in pharmaceutical benefits
Hospital medicines (NT-rådet)	Oncology, ATMPs, specialty	MA holder engages NT-rådet	Cyclical; aligned to launch windows	RCTs + Swedish RWE plan; commercial terms	National recommendation → regional implementation

Plan with the Registries in Mind: Strategic Notes for Sweden

Start with a national ask, not 21 separate ones.
For devices/digital of national relevance, go via MTP-rådet to secure a TLV health-economic evaluation—it prevents regional fragmentation.
Design the registry fields on day zero.
Your outcome and cost-utility story must be registry-ready (PROMs, time-to-diagnosis, LOS, re-admissions). Sweden will judge you on what the registries show, not just trial PDFs.
Make KVÅ your friend.
If your act isn’t cleanly KVÅ-codable, utilisation won’t be visible and your budget case weakens. Fix coding before pilots.
Budget for a two-step cycle.
Expect pilot/procurement (3–9 months) → national evaluation (6–12 months) → scale with registry RWE. Drugs follow TLV/NT-rådet with similar lifecycle reassessments.
Equity and productivity matter.
TLV and Regions value workforce/time savings and equitable access alongside outcomes—show both.

Denmark: Two Councils, One Discipline: Precision Reimbursement Through Evidence

Denmark has built one of Europe’s most coherent, data-driven reimbursement ecosystems, combining rigorous health-technology evaluation with real-world data integration and national procurement alignment.
Two expert councils dominate the system—the Danish Medicines Council (Medicinrådet) for pharmaceuticals and biologics and the Danish Health Technology Council (Behandlingsrådet) for medical technologies, digital health, AI, and clinical procedures. Both are underpinned by transparent methodology, structured timelines, and national interoperability rails (Sundhed.dk, MedCom, Danish Health Data Authority).

The result: a single-discipline culture where reimbursement depends not on lobbying but on clinical value, cost-effectiveness, and measurable patient outcomes.

Biopharma & Advanced Medicines Danish Medicines Council (Medicinrådet)

What it does

The Danish Medicines Council (DMC / Medicinrådet) evaluates hospital medicines, biologics, biosimilars, ATMPs, and companion diagnostics for inclusion in Denmark’s national hospital formulary.
It operates within a defined methodological grid, classifying each drug’s added clinical benefit (high, moderate, minor, or none) and assessing its cost per unit of benefit (incremental cost per responder or per QALY).

Who / where

MA holders and manufacturers submit applications to Medicinrådet. Assessment is led by two expert committees—one for oncology and one for all other therapeutics—supported by Amgros, which manages procurement and price negotiations.

Timelines

Pre-submission meeting: strongly advised 3–6 months pre-launch.
Assessment phase: ~16–20 weeks from dossier acceptance to recommendation.
Implementation: Positive recommendations become the standard of care across all five Danish regions; procurement is handled centrally via Amgros.

Evidence expectations

Direct head-to-head or adjusted indirect comparisons vs. relevant Danish comparators.
Incremental cost-effectiveness or cost-consequence models showing budget sustainability.
RWE follow-up: hospital registries and the Danish Medicines Agency datasets feed ongoing evaluation.
Transparency: all reports and evidence grids are publicly available at medicinraadet.dk.

Conversion

A positive recommendation → national hospital formulary listing, with procurement by Amgros and rapid clinical integration.
Negative or conditional recommendations trigger renegotiation or require new evidence.

MedTech, Digital Health, AI & Procedures — Danish Health Technology Council (Behandlingsrådet)

What it does

The Behandlingsrådet (Danish Health Technology Council, DHTC) assesses non-pharmaceutical health technologies—medical devices, diagnostics, AI-enabled tools, surgical techniques, and digital health solutions.
It mirrors DMC’s transparency and applies the same core principle: evidence-based value for money.

Evaluations include:

MedTech and IVD devices seeking national alignment;
Digital health and AI applications with measurable workflow or outcome benefits;
Surgical and procedural innovations requiring national comparability;
Screening or prevention programmes where data infrastructure allows follow-up.

Who / where

Applications can come from hospitals, innovators, or regional health authorities. DHTC’s Secretariat coordinates scoping, evidence appraisal, and final recommendations, published openly at behandlingsraadet.dk.

Timelines

Scoping and protocol: 2–3 months.
Evidence evaluation and modelling: 6–9 months.
Recommendation publication: within 12 months of project initiation.

Evidence expectations

Clinical evidence: comparative effectiveness and patient-relevant outcomes (mortality, LOS, quality of life).
Economic evidence: cost-minimisation, cost-utility, or cost-consequence analysis; explicit willingness-to-pay thresholds (no formal QALY threshold, but < DKK 300,000 per QALY considered favourable).
Implementation plan: workflow and data capture design embedded in regional EHR systems.
Real-world data (RWD): extraction from registries (LPR3), Sundhed.dk, and MedCom.

Conversion

DHTC recommendations are non-binding but highly influential—regions almost universally follow them for funding and procurement.
Technologies with strong clinical and economic signals often secure rapid regional uptake and are added to standard care pathways within months.

Diagnostics & IVD — From Hospital Pilots to National Codification

What it is

IVDs and laboratory tests are funded either:

Regionally, as part of hospital budgets, or
Nationally, when endorsed by DHTC or embedded in DMC-linked care pathways (e.g., CDx for targeted oncology).

Coding

Laboratory tests use SKS codes (Sundhedsvæsenets Klassifikations System), which must be created or updated for new assays.
Hospitals record usage in LPR3 (Landspatientregisteret) for national traceability.

Timelines

Pilot inclusion → SKS code creation: 3–6 months.
Formal DHTC evaluation or DMC linkage: up to 12 months.

Evidence

Analytical validity, diagnostic accuracy, and downstream utility—impact on treatment, hospitalisation, or cost.
For AI-enabled diagnostics, data sharing and GDPR compliance via MedCom standards are mandatory.

Digital Health, AI & Data Infrastructure

Digital reimbursement backbone

Denmark’s national e-health ecosystem is among Europe’s strongest:

MedCom: national secure messaging and data-exchange standard (FHIR, HL7).
Sundhed.dk: the national health portal providing clinicians and citizens unified access to records and data.
The Danish Health Data Authority (Sundhedsdatastyrelsen) governs interoperability, registries, and research use.

Funding and reimbursement

Regional budgets: most digital solutions are regionally procured and reimbursed via service contracts.
National pilots: DHTC may recommend funding trials under the National Programme for Digital Health (2022–2026).
Pharma-aligned DTx: integrated with DMC processes for drugs where digital companions contribute measurable outcomes (e.g., adherence, PROMS).

Evidence & governance

All digital health assessments must show clinical improvement, workflow efficiency, and budget neutrality.
GDPR and Danish Data Protection Act compliance are non-negotiable; data hosting must meet ISO/IEC 27001 and MedCom-certified standards.

Coding, Reimbursement & Procurement Systems

Setting	Coding / Tariff System	Description / Relevance
Hospital inpatient	SKS / NordDRG (Danish variant)	Procedures coded for cost tracing; supports DHTC evaluations & hospital budgets.
Hospital outpatient & community	SKS / regional tariff catalogues	Used for diagnostics, telehealth, and DTx reimbursements.
Pharmaceuticals	National DMC / Amgros	Price negotiation + inclusion in hospital formulary.
Digital health	Service contracts via regions / DHTC pilots	Regional reimbursement for validated digital solutions.

Timelines & Planning Matrix Denmark (2025)

Pathway / Scheme	Scope	Authority	Decision Window	Evidence Duration	Conversion / Outcome
DMC / Medicinrådet	Biopharma, ATMP, CDx	DMC + Amgros	16–20 wks	Continuous RWE	National hospital formulary listing
Behandlingsrådet (DHTC)	MedTech, IVD, digital, AI	DHTC	9–12 mo	Registry RWE	Non-binding national recommendation → regional funding
Regional Digital Contracts	Digital therapeutics, AI	Regions / DHTC	3–9 mo	Ongoing RWE	Regional reimbursement via service agreement
SKS / NordDRG	Inpatient/procedural	Danish Health Data Authority	Annual cycle	Continuous	Tariffed coding + DRG inclusion

Precision Planning for Denmark How to Approach the System

Start at the right council.
Drugs → Medicinrådet; Devices, Digital, AI → Behandlingsrådet. Align your evidence plan before dossier submission.

Design for integration, not isolation.
Denmark values workflow efficiency—build your economic case around nursing time, admissions avoided, and quality of life.

Exploit the data rails.
Ensure SKS codes, MedCom interoperability, and registry data points are defined pre-launch.
Without traceable utilisation, you cannot show value.

Budget for the full cycle.
Pre-submission (3–6 months) → Evaluation (6–12 months) → National uptake (within 3 months post-positive recommendation).
Real-world data collection is mandatory, not optional.

Leverage Amgros and DHTC synergies.
For combination product strategies (e.g., digital + drug, device + biologic), plan parallel submissions—one via DMC and one via DHTC—to synchronise evidence across domains.

In Denmark, discipline equals velocity.

Because decisions are transparent and evidence-based, innovators who plan early, align methodologically, and embed real-world data pipelines often achieve national adoption faster than in larger EU markets.
Every submission must answer one question: “What does Denmark gain, and can we prove it in data?”

Finland Data-First Reimbursement (Kanta + Findata as the engine)

Finland is engineered for evidence at scale. A single, widely used Kanta platform (which includes EHR, e-prescription, imaging summaries, and the patient portal MyKanta), along with a legal data-permit authority (Findata), under the secondary decisions are steered nationally (pricing/reimbursement, benefit design, and care-choice recommendations), but adoption and budgeting run through the 21 Wellbeing Services Counties (created in 2023). If you design your launch around Kanta-ready outcomes and a Findata permit plan, Finland pays for what you can prove.

1) Biopharma & Advanced Therapies (incl. “blockbusters”)

Regulators & payers

Fimea – national medicines/device regulator (if not EMA-centralised).
HILA – Pharmaceuticals Pricing Board: outpatient medicine reimbursement & price decisions (reference pricing, special reimbursement categories).
Kela – executes outpatient drug reimbursements; manages special reimbursement entitlements.
PALKO – Council for Choices in Health Care: what the public system covers (treatments, indications, sometimes diagnostics), with explicit value/ethics framing.
Wellbeing Services Counties – hospital/clinic budgets, procurement, implementation.

Routes & timelines

Outpatient drugs: MA (EMA/Fimea) → HILA dossier (price + reimbursement) → decision typically ≤180 days → Kela benefits in effect.
Hospital drugs: Assessed within regional hospital formulary processes; PALKO guidance and national clinical societies drive convergence; joint tenders are often via hospital purchasing alliances.
Managed access/uncertainty: outcome-based purchases or budget-cap contracts at the county/alliance level are feasible; PALKO positions + national registries (Kanta/RWE) enable reappraisal.

Evidence playbook

CEA/QALY and BIA are aligned to Finnish epidemiology and practice.
RWE plan: map endpoints to Kanta fields and national disease registries; pre-specify Findata data-linkage (e.g., prescriptions, encounters, labs, mortality) for 12–24-month re-review.
Equity and productivity (work absences and carer loads) are persuasive to counties.

Conversion

Positive HILA → national outpatient reimbursement.
For high-cost hospital drugs, regional formulary inclusion + national clinical positions → rapid spread; re-price/re-review with RWE.

2) MedTech, IVD & Companion Diagnostics (CDx)

How devices/tests are paid

No single national device list: counties fund devices/IVD in hospitals via budgets/procurement; outpatient testing is funded via provider contracts.
PALKO can issue coverage positions for tests/procedures (e.g., oncology pathways), accelerating national alignment.

CDx with medicines

Pair your CDx with the drug’s market access: present linked clinical utility (treatment selection, toxicity avoidance, survival) and a combined budget.
Hospital networks will include CDx when the therapy is commissioned; build a KV-coding and procurement plan with the same centres.

Timelines

Hospital pilot & procurement: 3–9 months (verification, training, IT integration).
PALKO guidance (when sought): 6–12 months from scoping.
New lab tariffs are local/contractual; national alignment follows PALKO/clinical society positions.

Evidence playbook

Analytical validity + change-in-management and outcome impact (time-to-treatment, avoided chemo, reduced LOS).
Cost-consequence for care pathway; BIA at county level.
RWE with Kanta variables; pre-arrange Findata permit for multi-county linkage.

Conversion

The transition from pilot to framework contract, and then to routine use across counties, is solidified by PALKO or national clinical guidance.

3) Digital Health & AI (DTx, RPM, decision support)

How it’s commissioned

Predominantly via county procurement and service contracts (SaaS/managed service).
National bodies (Ministry/THL) set architecture & security baselines; Kanta integration and Med-class software compliance (MDR/IVDR) are de facto entry tickets.

Timelines

Procurement & due diligence: 3–6 months if interoperable with county EHRs (Apotti/Epic; other regional vendors) and Kanta messaging.
Scaled adoption: 6–12 months after the first contract, if outcomes are visible in operational dashboards and MyKanta.

Evidence playbook

DTAC-style checklist (clinical safety, GDPR, information security, FHIR/SNOMED/LOINC mapping).
Pre-agree on RWE endpoints (admissions avoided, HbA1c reduction, PROMS, time-on-therapy).
Findata permit for secondary use → multi-county effectiveness and equity analysis.
For AI, add human-in-the-loop, bias monitoring, and a model drift plan.

Conversion

Positive pilots + RWE → multi-year framework agreements; PALKO opinions or national programmes can accelerate replication.

4) Governance, Coding & Data Rails (make these work for you)

Kanta – national services (EHR summary, e-Rx, imaging summaries, archiving, MyKanta).
Findata is a single data-permit authority enabling privacy-preserving linkage of health, social, prescription, mortality, and registration data for RWE and HTA.
THL – public health, registries, methods; hosts FinCCHTA (national HTA coordination) for device/diagnostic evaluations with regions.
PALKO – national coverage recommendations (what care is publicly funded).
Coding & tariffs – NordDRG (Finland) for inpatient; procedure codes and local tariffs at county level for outpatient/IVD; Kela drug tariff for outpatient medicines.
Security/interoperability – FHIR/HL7 and national terminology services; ISO 27001/27701; strong DPIA practice.

Timelines & Planning Matrix Finland (2025)

Pathway / Scheme	Scope	Who applies / where	Decision window	Evidence requirements	Conversion / outcome
HILA price & reimbursement	Outpatient medicines	MA holder → HILA	Target ≤180 days	CEA/QALY, BIA; Finnish comparators	National Kela reimbursement
Hospital formulary inclusion	Inpatient drugs	Manufacturer + hospital alliances	2–6 months	Comparative value, budget impact	Regional adoption; tenders
PALKO coverage position	Services, diagnostics, procedures	Stakeholders → PALKO	6–12 months	Clinical & ethical value, economics, equity	National guidance → rapid county alignment
MedTech/IVD hospital procurement	Devices, lab tests	Vendor + county/provider	3–9 months	Utility, pathway economics, IT integration	Framework contract; spread to neighbouring counties
Digital/AI service contracts	DTx, RPM, CDSS	Vendor + county	3–6 months	Safety, GDPR, FHIR, outcomes plan	Multi-year SaaS contracts; scale after RWE
Findata data-permit	Secondary-use RWE	Sponsor → Findata	~3–6 months (plan early)	Minimisation, linkage plan, analysis protocol	Nationwide, audit-ready RWE for re-appraisal

Design for Data: Finland Planning Notes (MedTech, IVD/CDx, Digital, Biopharma)

Lock the data pathway first.
Write your RWE Statistical Analysis Plan with Kanta fields and Findata linkage in mind; pre-map PROMs, clinical outcomes, and utilisation to national terminologies.
Pick your national lever.
Drugs → HILA (price/reimbursement) + county formulary; tests/procedures → aim for a PALKO position to avoid county-by-county drift.
Counties buy what integrates.
Show FHIR-based interoperability with the region’s EHRs (Apotti/Epic and others), and publish your information-security pack up front.
Prove value at county granularity.
Budget impact at the Wellbeing Services County level (bed days, staff time, transfers avoided) wins approvals faster than national averages.
Make reappraisal your friend.
Commit to 12–24-month RWE updates using Findata datasets; pre-negotiate price/volume adjustments contingent on outcomes.
For CDx/ATMP combos.
Build a single dossier linking tests and therapy outcomes (response, survival, toxicity, hospital days). Adoption moves in tandem when the evidence is packaged together.

Spain & Italy – Regional Pilots Maturing into National Frameworks

Spain operates through the RedETS early HTA network, regional innovation procurement in Basque, Catalonia & Galicia, and the National Cancer Plan 2021–2025 for molecular diagnostics funded via the EU RRF. Projects must report clinical and budget impact to the CISNS Council.

Italy has institutionalised conditional coverage through the AGENAS HTA Programme. Regional HTA networks feed national decisions and use Codici Temporanei for interim billing. The Oncology Precision Diagnostics Fund supports companion tests requiring QALY and ICER evidence.

Southern Europe’s two largest health systems are converging on structured, evidence-linked access. The playbook is consistent: prove value in a region, lock the evidence model early, and convert to national funding through RedETS (ES) or AGENAS (IT). Below is the practical version — what to file, who to see, how long it takes, how it gets coded, and what “good” looks like.

🇪🇸 Spain — Decentralised innovation; nationally coordinated decisions

System map (who does what)

CISNS + Ministry of Health (MSSSI): national policy, common benefits, final coordination.
AEMPS: medicines authorisation/safety; runs national therapy registries for specific high-cost drugs.
CIPM (DG Farmacia): pricing & reimbursement for medicines after EMA/AEMPS; uses IPT (Informe de Posicionamiento Terapéutico).
RedETS (ISCIII): early HTA for devices/diagnostics/digital; produces national recommendations.
Autonomous Communities (17 regions): budgets, procurement, local tariffs, hospital adoption.
Regional innovation/HTA agencies: AQuAS (Catalonia), OSTEBA (Basque), Avalia-t/ACIS (Galicia), etc. — run pilots, PPI/PCP tenders, and supply RedETS with data.

1) Biopharma & Advanced Therapies (incl. “blockbusters”)

Route & timeline (typical)

EMA/AEMPS MA → submit to CIPM with IPT and economics.
CIPM P&R decision: ~6–9 months from valid dossier.
Regional formulary adoption: 1–3 months after CIPM; local budget impact rules apply.
Post-listing RWE: national/regional registries (incl. VALTERMED-style outcome monitoring when required) → periodic reappraisals.

Dossier essentials

IPT-aligned clinical package (comparators relevant to Spanish practice).
CEA/QALY (Spain tends to cite €25–30k/QALY as an informal band) + Budget Impact with regional sensitivity.
RWE plan: endpoints, sources (hospital data lakes, national registries), and analysis windows (12–24 months).

Risk-share tools

Outcome-based agreements (CAR-T, ATMPs), caps, or staged uptake tied to RWE milestones.

Common pitfalls

Common pitfalls include under-specifying regional budget lines, with Spain leading the way in execution.
Weak alignment with IPT comparators: → rework.

2) MedTech, IVD & Companion Diagnostics (CDx).

Early validation & piloting

RedETS defines the scope of the project and assigns an evaluator, typically through AQuAS, OSTEBA, or Avalia-t.
The preferred approach is to conduct a pilot through PPI/PCP, which is co-funded by the EU RRF, and then incorporate the pilot’s real-world evidence (RWE) into RedETS.

Coding & money flows

Inpatient: CMBD/DRG (hospital episode) + procedure codes (Nomenclátor Sanitario).
Outpatient diagnostics: enter the SNS common services portfolio (Cartera Común) after RedETS validation.
Use regional catalogue codes temporarily while evidence accumulates to demonstrate utilisation and costs.

Timelines

Pilot call → award → 9–18 months execution.
RedETS HTA: 6–12 months (parallel if evidence is mature).
CISNS inclusion requires a national green light before regions can adopt it into their tariffs and formularies.
The entire process, from the first pilot to national inclusion, is realistically expected to take 24 to 36 months.

Evidence

The evidence includes analytical/clinical validity, changes in management, a health-economic model (CEA/BIA), and a registry-ready RWE plan, with a re-evaluation typically occurring every three years.

CDx

Tie the test → therapy chain to IPT: response, survival, toxicity avoided; submit paired economics (test + drug).

3) Digital Health & AI

Commissioning

Regional tenders (PPI/PCP) will be converted into service contracts, and national alignment will occur through their inclusion in the SNS digital catalogue after evaluation.
The national strategy for 2021–2026 funds telemonitoring, AI decision support, and interoperability (RRF).

Requirements

The requirements include ENS cybersecurity, compliance with GDPR, integration of EHR/PACS/RIS systems using IHE profiles, and the establishment of audit trails.
Outcomes: avoided admissions, LOS, ED revisits, PROMs/PREMs, workforce capacity.

RWE

Prefer multi-region dashboards; pre-agree fields with RedETS to ease national adoption.

Spain “How to win” checklist

Please select two regions (e.g., Catalonia and Basque) for the initial wave of pilots, and ensure your endpoints are pre-aligned with
Please file temporary regional codes immediately after the pilot to trace costs and volumes.
Submit economics twice: national (CIPM/RedETS) and region-granular BIA (ICU days, staff time, bed turnover).
Create a CISNS conversion pack: 4-page executive + RWE plan + coding sheet (CMBD/DRG, Nomenclátor, outpatient path).
For companion diagnostics (CDx), create a linked dossier that combines the drug and test information, as separate files hinder uptake.

Italy Regional engines; national HTA spine (AGENAS PNHTA)

System map (who does what)

AIFA: Pricing & Reimbursement (P&R) for medicines; Managed Entry Agreements (MEAs) via national registries.
AGENAS manages the PNHTA, which is a single national process that consolidates regional HTA into national recommendations for devices, diagnostics, and digital solutions.
Regions: hospital budgets, procurement, and early pilots (Lombardy, Veneto, Emilia-Romagna, Tuscany, Lazio, and Puglia are frequent leaders).
LEA/CNA-LEA: The national benefit basket—what’s universally covered.

1) Biopharma & Advanced Therapies

Route & timeline

EMA MA → AIFA P&R (price, reimbursement class)—target: ≤180 days.
Temporary inclusion/MEA for high-uncertainty products (12–24 months typical) with AIFA registry obligations.
The reappraisal process using Real-World Evidence (RWE) will lead to either permanent inclusion or a renegotiation of terms.

Dossier essentials

The cost-effectiveness analysis (CEA) and quality-adjusted life year (QALY) metrics, using Italian comparators, often cite a practical ceiling of €40,000 to €50,000 per QALY.
The budget impact should be analysed with sensitivity to regional differences, specifically between the North, Central, and Southern regions.
The registry plan includes tracking outcomes, adherence, discontinuation rates, and costs associated with AIFA registries within the OsMed ecosystem.

Watch-outs

Clock stops are common if the MEA terms are vague or the registry fields were not operationalised before launch.

2) MedTech, IVD & Companion diagnostics.

Governance & rails

PNHTA (AGENAS) consolidates regional HTA into a national recommendation.
Codici Temporanei: temporary billing identifiers for devices/tests while evidence accumulates (valid up to 3 years, renewable).
LEA: permanent national funding was once included; until then, regional budgets pay.

Regulatory plumbing should be ready.

Mapping of the CND (Italian device nomenclature), registration in the BD/RDM (national device database), and ensuring UDI traceability are necessary steps.
For IVDs: lab accreditation proof + analytical validity package.

Route & timeline

Regional pilot (e.g., Veneto/Emilia-Romagna) → Codice Temporaneo → submit PNHTA → national evaluation 9–18 months → LEA inclusion (tariff set) or MEA-style renewals.

Evidence

The analysis includes comparative effectiveness against the current protocol, implementation feasibility, cost-effectiveness analysis (CEA) and budget impact analysis (BIA) with region-specific costs, as well as a real-world evidence (RWE) plan that often involves hospital consortia.

CDx

Use ACC (Alleanza Contro il Cancro) labs & oncology networks; pair CDx with AIFA’s therapy registry to prove utility (time-to-treatment, toxicity avoided).

3) Digital Health & AI

Financing & tariffs

PNRR pours capital into hospital digitisation, telemedicine platforms, and AI pilots.
Telemedicine Tariffs (2023): national reimbursement for teleconsultation/telemonitoring under LEA, with regional implementation rules.
DTx/AI can use Codici Temporanei regionally while building RWE.

Must-haves

Interoperability of FSE/FSE2.0 (national EHR), compliance with PDND (national cloud) and GDPR, and a robust clinical safety file are essential requirements.
Outcomes meaningful to pathway capacity (clinic slots freed, LOS, ED bounce-backs).

Italy — “How to win” checklist

Start in two “HTA-mature” regions (Lombardy + Emilia-Romagna or Veneto + Tuscany). Bake Codice Temporaneo into your start-of-care pack.
Build your PNHTA storyline from day one: endpoints, comparators, and sites that will feed the national RWE.
Synchronise device/IVD regulatory (CND/BD-RDM/UDI) with coding; lack of a clean CND link slows tariffs.
For biologics/ATMPs, negotiate MEA terms (payment-by-results or cap) before the AIFA meeting; arrive with registry fields prototyped.
Prepare an LEA conversion pack: 2-pager + economics + three use cases with capacity gains (OR minutes, beds, staffing).

Coding, Data & “Make-it-Real” rails (quick reference)

Rail	Spain	Italy
Inpatient	CMBD/DRG + Nomenclátor procedure codes	SDO + DRG; ICD-9-CM still used for many regions; moving gradually; tariffs regionally set
Outpatient diagnostics	Cartera Común (SNS) after RedETS validation	LEA/CNA-LEA after PNHTA; before that → regional tariffs
Temp codes	Regional catalogue codes during pilots	Codici Temporanei (≤3 years, renewable)
Drug registries	National therapy registries; VALTERMED-style monitoring when required	AIFA registries/OsMed (mandatory for MEAs)
Innovation pilots	PPI/PCP (RRF) via AQuAS/OSTEBA/Avalia-t	Regional pilots via leading regions; PNRR supports infra/AI

Southern Europe — Playbook

Pick your proving grounds.
Spain: Catalonia (AQuAS) + Basque (OSTEBA/BIOEF). Italy: Lombardy/Emilia-Romagna/Veneto/Tuscany. Choose two; design identical endpoints so evidence merges cleanly.
Lock the conversion path on day zero.
Spain: pilot → RedETS → CISNS/Cartera. Italy: pilot + Codice Temporaneo → PNHTA → LEA. Build the conversion pack up front.
Code early, count everything.
Request temporary codes immediately after first inclusions (regional-ES, Codici Temporanei-IT). If it’s not coded, it didn’t happen.
Model capacity, not just QALYs.
Southern systems reward LOS reductions, theatre minutes saved, and staff time released. Make those the headline numbers in BIA.
RWE isn’t optional.
Commit to 12–24-month registry-grade RWE with predefined fields and privacy-compliant linkage. Promise a re-appraisal moment and bring it.
Bundle CDx with drug (and vice versa).
Paired dossiers convert faster than separate files. Put the test→treatment chain and economics into one story.

These initiatives align with OECD and WHO Adaptive Pathways principles to enable proportional, evidence-based decision-making for high-impact technologies.

EU-Wide Frameworks That Supercharge Evidence & Coding Alignment (2025→2028)

Why this matters: these EU rails let you standardise comparators, pool multi-country RWD, and convert pilots into permanent reimbursements faster—especially for MedTech, IVD/CDx, Digital/AI, and Biopharma/ATMPs.

1) EU HTA Regulation (Regulation (EU) 2021/2282) — Joint Clinical Assessments (JCA)

What it is: A binding EU framework for Joint Clinical Assessment and Joint Scientific Consultation that Member States must use in national HTA. Applies from 12 Jan 2025 (phased scope).
Why you care (keywords): Harmonised comparators, single evidence package, less duplicative HTA, faster national decisions.
How to use it:

Build protocols to JCA PICO early; book Joint Scientific Consultation to lock endpoints and comparators.
Align MedTech/IVD study designs to anticipated device JCA scope.
Timeline: In force & applicable from 12 Jan 2025; JCAs roll out by product class per Commission calendar.

2) European Health Data Space (EHDS) — Cross-border Primary & Secondary Use

What it is: The first sector-specific EU data space enabling cross-border access, sharing and reuse of electronic health data (primary care continuity + secondary-use permits for research/HTA/RWE). The OJ published it on 5 Mar 2025, it enters into force on 26 Mar 2025, and the transition is then staged.
Why you care (keywords): Federated multi-country RWD, secondary-use permits via HealthData@EU, standard terminologies → cleaner, audit-ready RWE for HTA/reappraisal.
How to use it:

Design your data model to EHDS artefacts (metadata, semantics) and plan secondary-use requests for multi-state coverage-with-evidence studies.
Timeline: Enters into force March 26, 2025; phased operationalisation follows the Council/Commission roadmap.

3) DARWIN EU (EMA) — Pan-EU Real-World Evidence on Medicines

What it is: EMA’s Data Analysis and Real World Interrogation Network delivering decision-grade RWE to EMA/national regulators across the product lifecycle (safety, effectiveness, utilisation).
Why you care (keywords): Regulatory-grade RWE, protocolled analyses that can underpin label changes, risk minimisation, and HTA reassessments.
How to use it:

Map your post-authorisation evidence needs to DARWIN EU feasibility; pre-specify outcomes consistent with EMA HTA parallel advice.
Status/timeline: Coordination centre running; studies ongoing and expanding through 2025.

4) EHDEN (European Health Data & Evidence Network) — OMOP-CDM at Scale

What it is: The EU’s flagship federated data network (OMOP-CDM) with certified partners and an academy, now transitioning to a foundation while continuing to support HTA/market-access RWE.
Why you care (keywords): Rapid data harmonisation, multi-site observational studies, patient-level prediction pipelines; supports outcomes-based models for procurement/MEAs.
How to use it:

Harmonise your endpoints to OMOP; recruit certified data partners; reuse EHDEN Academy training to harden your RWE methods.
Status: Foundation/academy active; 2025 deliverables highlight outcomes-based modelling feasibility.

5) AI Act + Health AI Enablers — Compliance Meets Reimbursement

What it is: The EU AI Act (risk-based regulation) with staged obligations (including GPAI guidance and high-risk medical AI duties). The Commission and the new AI Office are issuing updates/guidance through 2025; healthcare adoption is also funded under EU4Health and DEP pilots tied to HealthData@EU.
Why you care (keywords): Model risk management, post-market monitoring, bias/drift controls, technical documentation—all now feed payer re-evaluation and renewal of AI-linked reimbursement.
How to use it:

Build a model lifecycle file (data provenance, monitoring, human-in-the-loop). Map to payer KPIs (LOS, readmissions, time-to-diagnosis).
Timeline: Law in force; GPAI & high-risk obligations phase during 2025–2026; further guidance incoming.

6) IHI (Innovative Health Initiative) — De-risking Evidence Generation

What it is: Horizon Europe is a public-private partnership across pharma, biotech, MedTech, imaging & digital, and funding cross-sector projects that create shared evidence frameworks, reference datasets, and validation toolchains.
Why you care (keywords): Non-dilutive funding to co-develop infrastructure (registries, datasets, algorithms) that your HTA/reimbursement dossier can cite.
How to use it:

Target calls that create common disease-area evidence; design WPs that deliver HTA-ready endpoints and economic sub-studies.
Timeline: annual work programs and calls; 2024–2025 WP active, with further topics in the pipeline. IHI I

Fast-Track Playbook (what to actually do)

Pre-spec your JCA story. Write your pivotal/confirmatory protocol to JCA PICO; book Joint Scientific Consultation early. (Keyword: EU HTA compliance.)
Engineer EHDS-ready RWE. Pick outcomes you can pull cross-border under EHDS secondary use; pre-map semantics (SNOMED, LOINC, ATC). (Keyword: EHDS secondary-use permits.)
Leverage federated networks. Use DARWIN EU/EHDEN to answer safety-effectiveness questions and to support coverage with evidence development (CED). (Keywords: OMOP-CDM, federated analytics.)
Make AI reimbursement-proof. Align AI Act technical documentation with payer KPIs (LOS, readmissions, throughput) and plan post-market monitoring that doubles as RWE for re-listing.
Co-fund your evidence. Build an IHI consortium to de-risk registries/algorithms that serve both HTA and pricing negotiations.

Temporary Coding – The Hidden Engine of Evidence Generation

Country	Mechanism	Function
France	LPPR Code Transitoire	Temporary reimbursement during HAS evaluation.
Germany	OPS / EBM Draft Codes	Billing before DRG integration for cost tracking.
UK	OPCS Experimental Fields	Track pilot procedures and outcomes for NICE EVA or MTFM.
Italy	Codici Temporanei	Interim billing identifiers during AGENAS evaluation.
Sweden	KVÅ Codes	Registry linkage for QALY-based outcome analysis.
Belgium	NIHDI Temporary Nomenclature	Supports digital health pilots under mHealthBelgium Level 3.

Temporary codes guarantee traceability and statistical robustness, converting early clinical use into auditable RWE that supports adaptive HTA and permanent funding.

Conclusion – From Evidence to Access

Across Europe, a quiet revolution has taken hold.
Reimbursement no longer waits passively for data — governments are now paying to generate it.

Public budgets are now funding the studies that determine long-term payment, including France’s Article 51 pilots, RIHN 2.0 diagnostics, Germany’s §137e coverage-with-evidence studies, and NUB (the Netherlands’ Voorwaardelijke Toelating, Belgium’s mHealthBelgium Level 3, and the Nordic Registry networks all treat evidence not as a commercial burden but as public infrastructure—essential to responsible adoption.

At the European level, the new EU HTA Regulation, EHDS, and DARWIN EU make RWE a cross-border currency: clinical, operational, and economic data can now move as freely as the therapies they describe. Even the AI Act converts post-market monitoring into a reimbursable obligation, aligning algorithmic performance with payment renewal.

For innovators, the change marks a profound shift.
Europe has moved from “no data, no pay” to “generate data — and we’ll pay you to do it.”
Public agencies are co-financing pilots, registries, and real-world validation because they see evidence as the foundation of sustainability, not merely regulation.

The result is a continental ecosystem where proof and payment grow together —
where the smartest route to market access is not lobbying for tariffs but building evidence that governments are already willing to fund.

Glossary of Key Terms—European Evidence, Reimbursement, and Access Frameworks

Accès Précoce (AAP– France)

Definition: France’s early-access mechanism for medicines with major expected clinical benefits before or immediately after market authorisation.
Function: Provides temporary, reimbursed access under CNAM funding while real-world evidence (RWE) is generated and CEPS pricing is negotiated.
Relevance: Anchors Coverage-with-Evidence-Development (CED) for high-impact pharmaceuticals and biologics; early market entry tied to post-authorisation data collection.

AGENAS (Italy)—Agenzia Nazionale per i Servizi Sanitari Regionali

Definition: The national agency coordinating Italy’s Health Technology Assessment (HTA) programme (PNHTA).
Function: It brings together the results of regional HTA and provides information to help decide on payments for devices, tests, and digital
Relevance: Creates the evaluation spine linking pilot evidence to national funding inclusion in the LEA (Livelli Essenziali di Assistenza) basket.

AI Act (EU)

Definition: Europe’s regulatory framework for artificial intelligence classifies medical AI as “high-risk”.
Function: Requires post-market monitoring, algorithmic performance audits, and transparency that directly tie into reimbursement renewal.
Relevance: Establishes evidence obligations for digital and AI-enabled diagnostics, integrating technical validity with economic sustainability.

Article 51 (France)

Definition: Experimental care-pathway law under the French Social Security Code.
Function: Allows ARS (regional health agencies) and hospitals to test new care models, diagnostics, or digital tools under temporary reimbursement.
Relevance: The core mechanism for real-world pilots; results inform national scale-up and permanent tariffs within “droit commun”.

Budget Impact Analysis (BIA)

Definition: An economic model estimating short- and medium-term financial consequences of adopting a technology within a specific payer budget.
Function: Complements cost-effectiveness analysis (CEA/QALY) by projecting cash-flow impact across health budgets.
Relevance: A required component in HAS, NICE, ZIN, TLV, and AGENAS submissions; decisive for large-scale adoption.

CISNS – Consejo Interterritorial del Sistema Nacional de Salud (Spain).

Definition: Spain’s national health coordination council linking the Ministry of Health with regional authorities.
Function: Approves new benefits and ensures HTA outputs from RedETS are integrated into the national reimbursement catalogue.
Relevance: The gateway for converting regional pilots into national reimbursement decisions.

Codici Temporanei (Italy)

Definition: Temporary reimbursement codes enabling billing during evidence generation for new devices, diagnostics, or digital tools.
Function: Maintain traceability of use and cost for HTA evaluation under AGENAS PNHTA.
Relevance: Provide the bridge between innovation and LEA inclusion; validity typically up to three years.

Coverage with Evidence Development (CED)

Definition: A policy model granting time-limited reimbursement conditional on the generation of real-world clinical and economic data.
Function: Ensures early patient access while managing uncertainty through structured follow-up studies.
Relevance: Core principle in Forfait Innovation (FR), §137e (DE), Voorwaardelijke Toelating (NL), and MEAs (IT).

DARWIN EU (EMA) – Data Analysis and Real-World Interrogation Network

Definition: The European Medicines Agency’s federated network for real-world data on medicines.
Function: Provides regulatory-grade evidence for post-authorisation safety, effectiveness, and HTA reappraisal.
Relevance: Enables multi-country RWE generation that national HTA bodies can reuse, reducing duplication of post-market studies.

DiGA Fast-Track (Germany)

Definition: BfArM-managed process granting digital therapeutics (apps) conditional reimbursement for 12 months pending evidence submission.
Function: Allows rapid inclusion in the statutory health insurance (SHI) benefit catalogue if positive health effects are demonstrated.
Relevance: Europe’s prototype for digital-health coverage with evidence defines standards for DTx evaluation.

EHDEN – European Health Data & Evidence Network

Definition: A federated network of research partners harmonising EU health data to the OMOP-CDM standard.
Function: Enables multi-site observational studies and real-world evidence analyses across Europe.
Relevance: Supports HTA-relevant economic and outcome modelling and feeds data into the DARWIN EU and EU HTA JCA workflows.

European Health Data Space (EHDS)

Definition: An EU-wide legal and technical framework for primary and secondary use of electronic health data across Member States.
Function: Facilitates cross-border access to anonymous datasets for research, HTA, and policy evaluation via HealthData@EU.
Relevance: Makes multi-country RWE feasible for reimbursement and re-evaluation; critical for EHDS-compliant data permits.

EU HTA Regulation (Regulation (EU) 2021/2282)

Definition: Binding regulation establishing a Joint Clinical Assessment (JCA) for medicines and selected medical technologies.
Function: Harmonises evidence requirements, comparators, and endpoints across Member States.
Relevance: Reduces duplication in national HTA and underpins evidence alignment for EU-wide reimbursement consistency.

Forfait Innovation (France)

Definition: A national coverage-with-evidence scheme that funds promising medical devices, diagnostics, and digital therapeutics.
Function: Provides 2–4 years of temporary reimbursement while manufacturers collect clinical and economic data under HAS oversight.
Relevance: The benchmark CED mechanism for MedTech and digital health in France often leads to LPPR/NABM listing.

HAS – Haute Autorité de Santé (France)

Definition: France’s independent health technology assessment authority.
Function: Appraises clinical benefit (Service Attendu, ASA) and economic value; manages Forfait Innovation, AAP, and RIHN evaluations.
Relevance: The central gatekeeper for all reimbursement routes in France; defines the RWE and economic evidence standards.

HTA – Health Technology Assessment

Definition: A multidisciplinary evaluation of a health technology’s clinical, economic, ethical, and social implications.
Function: Informs pricing, reimbursement, and guideline decisions across Europe.
Relevance: The common language of payers is now increasingly harmonised under the EU HTA Regulation.

Innovationsfonds (§92a SGB V – Germany)

Definition: A statutory innovation fund (~€200 million/year) financing integrated-care and digital-health pilots.
Function: Funds projects generating implementation and cost-effectiveness evidence for potential SHI adoption.
Relevance: Key public co-funding stream for RWE and system-level evaluations in Germany.

LEA – Livelli Essenziali di Assistenza (Italy)

Definition: The national “essential benefits basket” defines healthcare services reimbursed by Italy’s SSN.
Function: Technologies listed in LEA are automatically reimbursed nationwide; updates follow positive PNHTA conclusions.
Relevance: End goal for permanent reimbursement after Codici Temporanei or MEA phases.

LPPR – Liste des Produits et Prestations Remboursables (France)

Definition: National list of reimbursable medical devices and services.
Function: Provides permanent tariff codes and reimbursement rates once technologies complete the Forfait Innovation or pilot phase.
Relevance: The final destination for MedTech and IVD reimbursement in France.

Managed Entry Agreements (MEA – Italy)

Definition: Outcome-based or financial risk-sharing contracts between AIFA and manufacturers for innovative therapies.
Function: Allow early access while managing uncertainty via data-driven pricing adjustments.
Relevance: Embody Italy’s CED philosophy for high-cost or advanced-therapy medicinal products (ATMPs).

NUB (Neue Untersuchungs- und Behandlungsmethoden – Germany)

Definition: A temporary funding scheme for new diagnostic or therapeutic procedures in hospitals.
Function: Allows hospitals to negotiate supplementary payments before DRG integration.
Relevance: Provides real-world utilisation and cost data that feed into InEK’s DRG updates and permanent reimbursement.

PNHTA – Programma Nazionale di Health Technology Assessment (Italy)

Definition: National HTA programme integrating regional HTA outputs under AGENAS.
Function: Coordinates evaluation of devices, diagnostics, and digital tools for inclusion in the LEA.
Relevance: Creates a single evidence pathway from regional pilots to national funding.

RedETS – Red de Evaluación de Tecnologías Sanitarias y Prestaciones del SNS (Spain)

Definition: Spain’s national network for early HTA coordinated by the Institute of Health Carlos III (ISCIII).
Function: Assesses medical devices, diagnostics, and digital health technologies for national inclusion via CISNS.
Relevance: The gatekeeper for national reimbursement ensures pilots are evidence-driven and economically justified.

RIHN 2.0 – Référentiel des Innovations Hors Nomenclature (France)

Definition: A framework granting temporary reimbursement for innovative laboratory and AI-based diagnostic acts outside existing nomenclatures.
Function: Supports early access to novel diagnostics while mandating data capture for later HAS evaluation.
Relevance: The operational AI reimbursement system in France links early payment to real-world performance metrics.

Voorwaardelijke Toelating (Conditional Reimbursement – Netherlands)

Definition: A Dutch scheme enabling temporary inclusion of promising therapies or technologies in the Basic Health Insurance package.
Function: Provides national funding during defined evidence-generation periods, typically 2–3 years.
Relevance: Demonstrates the Netherlands’ balance of economic discipline and innovation support; evidence outcomes determine permanence.

ZIN – Zorginstituut Nederland (National Health Care Institute, Netherlands)

Definition: Dutch authority responsible for HTA, guideline development, and the Basic Health Insurance package.
Function: Conducts CEA/BIA reviews and determines whether technologies are “appropriate and effective” for reimbursement.
Relevance: A model for transparent cost-utility thresholds and continuous re-evaluation using RWE.

FREQUENTLY ASKED QUESTIONS

1) What is Coverage with Evidence Development (CED), and how is it operationalised in Europe?

Answer:
CED grants time-limited reimbursement while a pre-agreed evidence plan runs in routine care. Europe implements CED through:

France: Forfait Innovation (devices/IVD/digital), Article 51 (care models), AAP (medicines), RIHN 2.0 (AI/diagnostic acts), and PECAN (digital).
Germany: §137e Erprobungsstudien (formal payer trials), NUB (temporary DRG supplements), DiGA (DTx 12-month list-and-learn).
Netherlands: Voorwaardelijke Toelating (conditional listing in the basic package).
Italy: Codici Temporanei + PNHTA pipeline; MEA contracts via AIFA.
Belgium: mHealthBelgium Level 3 (temporary coverage); implants via national lists.
Nordics: registry-anchored adoption (e.g., TLV/MTP Council in Sweden).
Design pattern: clear endpoints, time box (12–48 months), economic plan (CEA + BIA), coding for traceability, and a conversion trigger (e.g., LPPR/LEA integration) if targets are met.

2) How should we structure a cost-effectiveness analysis (CEA) that resonates with EU HTA bodies?

Answer:

Perspective & horizon: Payer (country-specific) with disease-appropriate horizon (e.g., lifetime for oncology/ATMPs; 3–5 years for acute MedTech).
Comparator: The actual standard of care in that country (locked through early HTA/scientific advice).
Model: State-transition (Markov) or partitioned survival (oncology); include tunnel states for short-lived events (ICU, peri-op).
Utilities: EQ-5D-5L mapped or local value sets; age- and comorbidity-adjusted.
Costs: Micro-costing for hospital (staff time, consumables, OR minutes), nationally indexed tariffs, device price bands.
Outputs: ICER = \(\DeltaCost / Δ\DeltaΔQALY), NMB = \(\lambda \cdot \DeltaQALY − Δ\DeltaΔCost), scenario & PSA (≥1,000 iterations).
“What good looks like”: transparent assumptions, conservative uptake, and country-granular BIA alongside CEA.

3) What budget impact (BIA) details do payers expect for hospital technologies?

Answer:

Population: Incident and prevalent; care-pathway filters (eligibility, contraindications).
Resource shifts: OR time, length of stay (LOS), ICU days, readmissions, ED revisits, and re-ops.
Workforce: Clinician/nursing minutes, clinic slots, training curve.
Substitution effects: Device vs. legacy consumables; downstream drug use (e.g., antibiotics, biologics).
Price mechanisms: learning-curve discounts, framework pricing, device lifespan & maintenance.
Timeframe: 3–5 years with ramp-up; regional disaggregation (Spain/Italy/Germany).
Acceptance cues: Headline cost per patient and cost per bed-day saved; threshold analysis for key drivers.

4) How big should RWE samples be in CED pilots to influence reimbursement?

Answer:

Power to detect change-in-management (diagnostics) or hard outcomes (hospital LOS, readmissions).
For hospital MedTech, n≈150–400 patients per arm often detects LOS ≥0.5–1.0 day differences.
For diagnostics/CDx, power on treatment selection and time to treatment; n≈200–600 across sites.
For DTx/AI, design interrupted time series or stepped wedge with ≥6–12 months pre/post per site.
Multi-site: at least 3–5 centres with heterogeneity captured; pre-specify missing-data handling and site random effects.

5) How do we pick endpoints that survive HTA scrutiny and convert pilots to tariffs?

Answer:
Prioritise patient-relevant and system-relevant endpoints:

Patient: survival, complications, time-to-diagnosis/treatment, PROMS/PREMS, adverse events avoided.
System: LOS, theatre minutes, unplanned returns, ICU days, staff hours, avoided transfers.
Economic: cost per responder, cost per avoided admission, ICER, BIA deltas.
Align to guideline triggers (e.g., oncology tumour board decisions, sepsis bundles); ensure endpoints are automatically captured (EHR fields, registries).

6) How do temporary codes actually work, and why do they matter?

Answer:
Temporary codes (e.g., LPPR transitoire FR; Codici Temporanei IT; regional catalogue codes ES; OPS/EBM drafts DE) provide:

Traceability: activity and spend during pilots.
Data spine: utilisation for DRG recalibration or tariff setting.
Conversion lever: “If coded and beneficial, it becomes permanent.”
Request immediately post-approval, tie code issuance to the RWE plan, and publish coding guidance to clinical teams.

7) What makes or breaks a §137e (Germany) Erprobungsstudie application?

Answer:

Clear uncertainty addressable only in real-world care (not lab).
Prospective design with hard endpoints (complications, LOS, mortality) and health-economic data in the CRF.
Recruitment realism (centre network + screening logs).
OPS/EBM coding in the protocol.
G-BA stakeholder buy-in (societies, patients) evidenced by letters.
Conversion plan: DRG inclusion or EBM fee item post-positive results.

8) How do we prove clinical utility for IVD/CDx beyond diagnostic accuracy?

Answer:

Change-in-management: % treatment escalations/de-escalations attributable to test.
Time metrics: days to targeted therapy, time to surgery.
Outcomes: response rate, toxicity avoided (e.g., DPYD), progression-free survival.
Economic: cost per appropriately treated patient; drug wastage avoided; downstream utilisation.
Design: prospective registry with linked therapy data, tumour board documentation, and pre-specified economic read-outs.

9) What does a DiGA Fast-Track dossier need to succeed?

Answer:

Positive health effects (medical benefit or patient-relevant structural/process improvements) shown by at least a comparative study design.
Interoperability & security (interfaces, encryption, data minimisation).
Care-pathway integration (prescribing/activation logistics).
12-month evaluation plan: endpoints, sample, analysis; health-economic sub-study encouraged.
Pricing logic: value-based narrative and planned negotiation corridor with SHI funds.

10) How should AI devices plan post-market monitoring that also helps reimbursement renewal?

Answer:

Model lifecycle file: data provenance, versioning, bias metrics, drift detection, human-in-the-loop checkpoints.
KPI mapping: clinical (miss rates, triage accuracy), operational (report TAT), and economic (bed-days, clinic throughput).
Governance: change control, auditability, rollback plan.
Study type: rolling cohort with performance guarantees and site-level feedback loops; periodic payer-facing RWE briefs.

11) What are typical ICER/threshold expectations across key markets?

Answer (practical bands, not statutory):

UK (NICE): £20–30k/QALY (contextual up to ~£50k for end-of-life/rare).
France (HAS/CEESP): No formal threshold; ≤€50k/QALY is often treated as acceptable when budgets allow and clinical value is material.
Sweden (TLV): Contextual bands; higher tolerance for severe disease/large benefit.
Netherlands (ZIN): Severity-weighted thresholds (higher severity → higher €/QALY).
Italy/Spain: Thresholds are tacit; €25–40k/QALY bands are often referenced with strong BIA discipline.
Always pair ICER with a BIA that demonstrates affordability within programme budgets.

12) When do payers prefer cost-consequence over full cost-effectiveness models?

Answer:

Early MedTech with multiple pathway endpoints (e.g., time saved, bed turnover) not reducible to QALYs.
Service/AI interventions where operational gains drive value.
Local procurement decisions focusing on cash flow rather than lifetime health gains.
Still provide a CEA bridge for national HTA, but lead with cost-consequence for hospital buyers.

13) How do we write an RWE Statistical Analysis Plan (SAP) for multi-country EU use?

Answer:

Protocol alignment to EU HTA JCA PICO.
Data model: common data model (e.g., OMOP) with site-mapping rules and codelists.
Confounding control: propensity weighting/matching; sensitivity analyses; negative controls when feasible.
Missingness: pre-specify multiple imputation or complete-case; document MAR/MNAR assumptions.
Federated analysis: site-level scripts, centrally aggregated outputs, harmonised definitions, reproducible pipelines (versioned).

14) What’s the fastest practical path to national adoption in Spain for a device or digital tool?

Answer:

Pilot in two leading regions (e.g., Catalonia and Basque) via PPI/PCP.
Get temporary regional codes and publish site KPIs (LOS saved, clinic capacity).
Submit a RedETS dossier using pilot RWE + economics.
Seek CISNS inclusion into the Cartera Común.
Provide a 3-year re-evaluation plan and region-granular BIA to accelerate replication.

15) How do we make Codici Temporanei (Italy) convert to LEA?

Answer:

From day 0, set RWE milestones: recruitment pace, interim read-outs at 12/24 months, and site expansion.
The Tie Codice Temporaneo is used to clear clinical & economic KPIs (e.g., OR minutes saved, toxicities avoided).
Pre-align with AGENAS PNHTA reviewers; ensure CND nomenclature and BD/RDM device registration are clean.
Submit an LEA conversion pack: pooled RWE + CEA/BIA + implementation guide for regions.

16) What evidence does RedETS expect for diagnostics/AI beyond the clinical paper?

Answer:

External validity: multi-region, multi-vendor EHR/PACS/RIS.
Workflow: training time, false-positive work-ups, radiologist/pathologist time.
Equity: differential performance by site/population.
Economics: cost per avoided imaging/biopsy, TAT reduction → downstream savings; BIA at regional level.
Data protection: ENS class, DPIA summary, logging/audit trails.

17) How should we price digital therapeutics (DTx) under “list-and-learn” models?

Answer:

Anchor on outcomes: per-treated patient value share (e.g., avoided admission worth €X; price set at Y% of X).
Tiering: adherence-based pricing (active days), performance bonuses for exceeding KPIs.
Ceilings: annual caps per patient or per contract to protect payer risk.
Evidence cadence: quarterly dashboards + 12-month formal RWE update for price renegotiation.

18) How do we plan GDPR/EHDS-compatible secondary-use data flows?

Answer:

Data minimisation & purpose limitation in protocol.
Federated analysis whenever possible; PII stays local.
Terminologies: SNOMED-CT, LOINC, ATC, and ICD mapped to OMOP.
Governance: data-transfer agreements, role-based access, audit logs.
EHDS readiness: metadata descriptors, consent models, and a cross-border permit playbook once HealthData@EU nodes are live.

19) What are the top three reasons CED pilots fail to convert to permanent reimbursement?

Answer:

Endpoints miss payer priorities (e.g., no LOS or workforce impact).
Inadequate coding/traceability, so activity and cost savings can’t be proven.
Underpowered or poorly executed RWE (attrition, missingness, centre variability) without prespecified mitigation.

20) What does an “investment-grade” conversion dossier look like?

Answer:

Executive decision memo (≤4 pages): clinical effect, system impact, economics, safety.
Methods appendix: full CEA/BIA, SAP, PROTOCOL, CONSORT-style tables.
RWE annex: centre-level KPIs, equity cuts, sensitivity scenarios, data quality audit.
Implementation pack: coding sheet (temporary→permanent), procurement spec, training minutes, IT integration checklist.
Policy glidepath: how this fits EU HTA JCA, EHDS, and national budget plans; proposed review cycle (q12–24 months).

References

1. Cross-European / EU-level

1.1 Regulation (EU) 2021/2282 on Health Technology Assessment

Citation
European Parliament and Council. Regulation (EU) 2021/2282 of 15 December 2021 on health technology assessment and amending Directive 2011/24/EU. Official Journal of the European Union L 458, 22.12.2021.EUR-Lex+1

What this is
The core EU regulation that creates the Joint Clinical Assessment (JCA) framework from 2025 onwards and sets out how EU HTA cooperation will work for medicines and (later) devices. It’s the legal backbone for any discussion of EU-level evidence generation, joint reports, and HTA alignment.

URL
https://eur-lex.europa.eu/eli/reg/2021/2282/oj/eng

2. France – RIHN, Article 51, PECAN, HAS methods

2.1 RIHN 2.0 – Ministry of Health overview

Citation
Ministère de la Santé et de la Prévention. RIHN 2.0 : un soutien renouvelé à l’innovation pour les actes. 2025.sante.gouv.fr

What this is
Official French government page explaining the Référentiel des actes innovants hors nomenclature (RIHN) and how it supports early, temporary funding for innovative procedures outside existing nomenclatures. It explicitly describes the temporary coverage + data collection logic.

URL
https://sante.gouv.fr/soins-et-maladies/qualite-securite-et-pertinence-des-soins/biologie-medicale/rih

2.2 RIHN 2.0 – HAS application and data-collection requirements

Citation
Haute Autorité de Santé (HAS). Déposer une demande d’inscription au référentiel des actes innovants hors nomenclature (RIHN 2.0). 2024.Haute Autorité de Santé

What this is
HAS guidance on how to submit for RIHN 2.0. Crucially, it spells out that coverage is conditional on clinical and/or medico-economic data collection by the applicant to confirm benefit. “HAS guidance on applying for RIHN 2.0”

URL
https://www.has-sante.fr/jcms/p_3566839/fr/deposer-une-demande-d-inscription-au-referentiel-des-actes-innovants-hors-nomenclature-rihn-2-0

2.3 HAS Economic Evaluation Guide

Citation
Haute Autorité de Santé (HAS). Choix méthodologiques pour l’évaluation économique à la HAS – Guide méthodologique (version 2020, mise à jour 2025). 2025.Haute Autorité de Santé+1

What this is
The core French economic-evaluation methods guide used by CEESP/HAS. It sets out requirements for CUA, ICERs, perspective, discounting, sensitivity analyses, etc., and is the basis for economic components of conditional and routine reimbursement. “HAS methodological guide for economic evaluation”

URL
https://www.has-sante.fr/jcms/r_1499251/fr/choix-methodologiques-pour-l-evaluation-economique-a-la-has

2.4 Article 51 – Innovation in Healthcare

Citation
Ministère de la Santé et de la Prévention. Dispositif “Article 51” – Innovations organisationnelles pour la transformation du système de santé – Vous avez un projet ? 2025.sante.gouv.fr+1

What this is
Official portal for Article 51 LFSS 2018, which funds organisational and pathway innovations on a temporary, experimental basis with mandatory evaluation. Provides templates, eligibility criteria, and the project submission platform. “French Article 51 innovation in healthcare scheme”

URL
https://sante.gouv.fr/systeme-de-sante/parcours-des-patients-et-des-usagers/article-51-lfss-2018-innovations-organisationnelles-pour-la-transformation-du/article/vous-avez-un-projet

2.5 PECAN – Early Funding for Digital Medical Devices

Citation
G_NIUS / Ministère de la Santé. Prise en charge anticipée numérique (PECAN). 2024.G_NIUS+1

What this is
Government e-health portal explaining PECAN, the early funding scheme for digital medical devices (DMN). It describes 1-year exceptional funding by Assurance Maladie while evidence is finalised, explicitly framed as derogatory reimbursement linked to further data. “PECAN early reimbursement for digital medical devices in France”

URL
https://gnius.esante.gouv.fr/fr/financements/fiches-remboursement/prise-en-charge-anticipee-numerique-pecan

2.6 HAS Principles for DMN & PECAN

Citation
Haute Autorité de Santé (HAS). Principes d’évaluation de la CNEDiMTS – Volume 4 : Prise en charge anticipée des dispositifs médicaux numériques (PECAN). 2025.Haute Autorité de Santé+1

What this is
Technical methods document defining evidence standards for digital medical devices, including criteria for PECAN and LATM. It clarifies clinical, methodological and organisational-impact requirements for DMN reimbursement. HAS evaluation principles for digital medical devices and PECAN”

URL
https://www.has-sante.fr/upload/docs/application/pdf/2025-09/principes_devaluation_de_la_cnedimts_prise_en_charge_anticipee_pecan.pdf

3. Germany – Erprobung, NUB, DiGA/DiPA, IQWiG

3.1 G-BA “Erprobungsregelung” for High-Risk Devices

Citation
Gemeinsamer Bundesausschuss (G-BA). Erprobung neuer Untersuchungs- und Behandlungsmethoden (§137e SGB V) – Erprobungsregelung. 2024.g-ba.de+1

What this is
Official G-BA page on “Erprobung”, i.e. conditional coverage with evidence development for new, mostly high-risk device procedures in inpatient care. It explains pathways from §137h and the design of mandated clinical trials. G-BA Erprobungsregelung conditional coverage scheme”

URL
https://www.g-ba.de/themen/methodenbewertung/bewertung-erprobung/erprobungsregelung/

3.2 IQWiG General Methods (Version 7.0)

Citation
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). General Methods – Version 7.0. 2023.iqwig.de+1

What this is
IQWiG’s overarching methods paper. It sets out standards for benefit assessment, evidence grading, and economic evaluation that underpin G-BA decisions, including device and diagnostic appraisals that sit behind conditional funding.IQWiG General Methods 7.0.

URL
https://www.iqwig.de/methoden/general-methods_version-7-0.pdf

3.3 NUB – InEK Application Portal

Citation
InEK Institut für das Entgeltsystem im Krankenhaus. Neue Untersuchungs- und Behandlungsmethoden (NUB) – Anfrageformular und Verfahrenseckpunkte. 2024.g-drg.de+1

What this is
Official InEK / GKV information for NUB applications, used to obtain temporary supplemental payments for new hospital procedures before they are fully integrated into the DRG system. This is effectively a transitional reimbursement mechanism for innovative technologie “German NUB application process for new hospital procedures”

URL
https://www.g-drg.de/neue-untersuchungs-und-behandlungsmethoden-nub/drg/anfrageformular

3.4 BfArM – DiGA and DiPA Framework

Citation
Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Digitale Gesundheits- und Pflegeanwendungen (DiGA, DiPA). 2024.BfArM+1

What this is
Official BfArM information on DiGA (digital health applications) and DiPA (digital care applications), including evaluation criteria, legal basis (§139e SGB V) and the role of the DiGA Directory for reimbursement. “BfArM DiGA and DiPA reimbursement framework”

URL
https://www.bfarm.de/DE/Medizinprodukte/Aufgaben/DiGA-und-DiPA/_node.html

3.5 DiGA Directory

Citation
BfArM. DiGA-Verzeichnis – Verzeichnis digitaler Gesundheitsanwendungen. 2024.diga.bfarm.de

What this is
The official directory listing all approved and reimbursable DiGAs, including those admitted provisionally with an evidence-generation obligation. Each entry shows indications, evidence status, and pricing. official DiGA directory of reimbursed digital health apps”

URL
https://diga.bfarm.de/de

4. Netherlands – Voorwaardelijke Toelating (Conditional Admission)

4.1 Conditional Admission of Care

Citation
Zorginstituut Nederland. Voorwaardelijk toegelaten zorg. 2024.zorginstituutnederland.nl

What this is
Explains how the Dutch Minister of Health can grant temporary, conditional inclusion of care in the basic package while evidence is completed. It’s the main Dutch template for coverage with evidence development, with clear criteria and timelines “Dutch conditional admission scheme (voorwaardelijke toelating)”

URL
https://www.zorginstituutnederland.nl/verzekerde-zorg/v/voorwaardelijke-toegelaten-zorg

4.2 Conditional Admission – Orphan and Exceptional Medicines

Citation
Zorginstituut Nederland. Voorwaardelijke toelating weesgeneesmiddelen, conditionals en exceptionals. 2024.zorginstituutnederland.nl

What this is
Detailed explanation of conditional admission for orphan and exceptional medicines, including how ZIN evaluates “stand van de wetenschap en praktijk” at the end of the conditional period and advises the Minister on permanent inclusion. Dutch conditional access, orphan drugs conditional reimbursement, ZIN assessment, coverage with evidence.

URL
https://www.zorginstituutnederland.nl/werkagenda/voorwaardelijke-toelating-weesgeneesmiddelen-conditionals-en-exceptionals

5. Spain – RedETS and Regional HTA (AQuAS, AETSA)

5.1 RedETS – National HTA Network

Citation
Ministerio de Sanidad. Red Española de Agencias de Evaluación de Tecnologías y Prestaciones del SNS (RedETS). 2024.Redets+1

What this is
Official site for RedETS, the Spanish HTA network that coordinates evaluations across regions. It emphasises quality, efficiency and sustainability in HTA and includes links to HTA reports and patient-involvement strategy.RedETS Spanish HTA network for medical technologies

URL
https://redets.sanidad.gob.es/

5.2 AQuAS – HTA of Health Technologies (Catalonia)

Citation
Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Tecnologies sanitàries. 2024.aquas.gencat.cat+1

What this is
Regional Catalan HTA body describing its work on evaluation of health technologies, including devices, diagnostics, complex organisational innovations and digital health. AQuAS is heavily involved in innovation pilots and RWE-style evaluations. Anchor text: “AQuAS health technology assessment in Catalonia”

URL
https://aquas.gencat.cat/ca/fem/avaluacio/tecnologies-sanitaries/

5.3 AETSA – Andalusian HTA Agency

Citation
Servicio de Evaluación de Tecnologías Sanitarias de Andalucía (AETSA). Evaluación de Tecnologías Sanitarias de Andalucía – Qué hacemos. 2024.aetsa.org+2aetsa.org+2

What this is
Explains AETSA’s mission to support decision-making on health technologies through HTA reports, rapid assessments, guidance and early-awareness work. AETSA undertakes evidence generation and evaluation for devices, diagnostics and organisational changes in Andalusia. AETSA – Andalusian health technology assessment agency”

URL
https://www.aetsa.org/

6. Italy – PNHTA, AIFA Managed Entry Agreements

6.1 PNHTA – National HTA Programme for Medical Devices (News)

Citation
AGENAS. Programma Nazionale HTA Dispositivi Medici 2023–2025 – aggiornamento scheda di segnalazione delle tecnologie sanitarie. 2025.agenas.gov.it+2agenas.gov.it+2

What this is
News and official documentation on the National HTA Programme for medical devices (PNHTA-DM), including the updated submission form for technologies to be prioritised for national HTA. It explicitly references alignment with the EU HTA Regulation. Italian National HTA Programme for medical devices (PNHTA-DM)”

URL
https://www.agenas.gov.it/aree-tematiche/comunicazione/primo-piano/2394-programma-nazionale-hta-dispositivi-medici-2023-2025-scheda-di-segnalazione-delle-tecnologie-sanitarie-aggiornamento

6.2 PNHTA – Technical Programme (Gazzetta Ufficiale)

Citation
Ministero della Salute / AGENAS. Programma Nazionale HTA Dispositivi Medici 2023–2025 – Proposta tecnica AGENAS (Allegato 1). Gazzetta Ufficiale, 2023.Gazzetta Ufficiale+1

What this is
The technical attachment in the Gazzetta Ufficiale detailing the vision, mission, governance, and processes for Italy’s PNHTA, including prioritisation, assessment, appraisal, implementation, monitoring and regional collaboration. technical programme of Italy’s PNHTA for medical devices

URL
https://www.gazzettaufficiale.it/atto/serie_generale/caricaArticolo?art.codiceRedazionale=23A04922&art.dataPubblicazioneGazzetta=2023-09-05&art.flagTipoArticolo=1&art.idArticolo=1

6.3 AIFA – Managed Entry Agreements and Monitoring

Citation
Agenzia Italiana del Farmaco (AIFA). Aggiornamento procedura Managed Entry Agreements. 2024.AIFA+2AIFA+2

What this is
Official AIFA update on the procedure for Managed Entry Agreements (MEAs) and use of the AIFA Registries platform to manage conditional reimbursement, outcome-based contracts and refund mechanisms. AIFA Managed Entry Agreements and monitoring procedures”

URL
https://www.aifa.gov.it/-/aggiornamento-procedura-managed-entry-agreements

7. United Kingdom – NICE & MedTech Funding Mandate (for comparison)

7.1 NICE Health Technology Evaluations Manual

Citation
NICE. NICE health technology evaluations: the manual (PMG36). 2022, updated 2025.NICE+1

What this is
NICE’s main methods manual for Health Technology Evaluations, covering clinical and economic methods, stakeholder consultation and decision-making. Useful in your blog as a comparator framework to EU conditional schemes. “NICE health technology evaluation manual (PMG36)

URL
https://www.nice.org.uk/process/pmg36

7.2 NHS England – MedTech Funding Mandate Guidance

Citation
NHS England. Medical technology (MedTech) funding mandate policy guidance. Effective from 1 April 2024.NHS England+1

What this is
Updated guidance on the MedTech Funding Mandate, which guarantees national NHS reimbursement for selected technologies that are NICE-approved and cost-saving, giving a real-world example of centralised, criteria-based innovation funding rather than classical conditional reimbursement.“NHS England MedTech Funding Mandate policy

URL
https://www.england.nhs.uk/long-read/medical-technology-medtech-funding-mandate-policy-guidance/

How to secure conditional reimbursement in Europe. Get paid!

Executive Summary: Conditional Reimbursement and Evidence-Linked Market Access Across Europe

France now offers the most advanced conditional reimbursement system in Europe—integrating Forfait Innovation, Article 51, Accès Précoce, PECAN, and RIHN 2.0 to fund biotech, pharma, MedTech, and AI innovations while real-world evidence is collected.

Forfait Innovation (FI) coverage with Evidence Development for MedTech & AI Diagnostics

Article 51: Experimental Care Pathways

Accès Précoce (AAP) Early Access for Biotech & Pharmaceutical Innovations

Companion Diagnostics (CDx) and Precision Medicine: Get Paid!

PECAN — Digital Health Fast-Track

RIHN 2.0—Transitional Reimbursement for Innovative Labs and AI Acts

PHRC & PRME Public Research Backbone: Get paid!

Timelines & Planning Matrix — Conditional Reimbursement in France (2025)

Proper planning prevents poor performance

Learn how biotech and pharma innovators secure reimbursement in France through AAP early access, CEPS pricing, and real-world evidence strategies.

1. Accès Précoce (AAP): Time-Limited Reimbursement with RWE Commitments

2. CEPS Pricing and Economic Assessment

3. Integration with the PHRC–PRME Research Backbone

4. Real-World Data and Lifecycle Management

5. Emerging Directions. From AAP to European Convergence, you get paid earlier

Netherlands Managed Experimentation + Economic Discipline (Biotech, MedTech/IVD, Digital & AI)

1) Biotech & Pharmaceuticals Voorwaardelijke Toelating (Conditional Inclusion)

2) MedTech & IVD — Insurer-Contracted Pilots + NZa “Kleinschalige experimenten”

3) Digital Health & AI — Funded via Existing Benefit Rules + NZa Digital Guide

4) National Research & Policy Scaffolding — ZonMw, Health Deals, Horizonscans

Timelines & Planning Matrix Netherlands (2025)

Discipline Delivers Access: Strategic Planning for Market Entry in the Netherlands

United Kingdom Early Evaluation → Managed Access → Mandated Adoption

1) MedTech & Devices

2) Digital Health & AI

3) Diagnostics, IVD & Companion Diagnostics

4) Cancer Medicines & Highly Specialised/Innovative Drugs

5) The (new) 10-Year Health Plan — Opportunity SignalsUK Market Access Timelines & Planning Matrix (2025)

NICE EVA (Early Value Assessment – MedTech, AI, Digital)

MedTech Funding Mandate (MTFM)

DTAC (Digital Technology Assessment Criteria)

AI in Health and Care Award (Phases 1–4)

NICE DAP (Diagnostics Assessment Programme)

NHS Genomic Medicine Service – Genomic Test Directory (GTD)

ILAP → NICE TA / HST (Innovative Licensing and Access Pathway)

Cancer Drugs Fund (CDF) & Innovative Medicines Fund (IMF)

One-Page Summary Table (Cross-Pathway View)

Plan. Prove. Procure. Strategic Planning for the UK

Germany: Pragmatic Early Access & Real-World Data Discipline

1) Inpatient MedTech/IVD — NUB → DRG integration

2) Coverage with Evidence Development §137e Erprobungsstudien (G-BA)

3) Digital & AI — DiGA Fast-Track (and DiPA for nursing)

4) Outpatient adoption & coding — EBM (community) and OPS (hospital)

5) Pharma & “blockbuster” drugs AMNOG (early benefit assessment)

6) Companion diagnostics & IVD

7) National research & digital rails

Timelines & Planning Matrix — Germany (2025)

Plan. Prove. Pay. Strategic Planning for Germany

Belgium Pyramid-First, Registry-Ready

1. Digital Health & AI — The mHealthBelgium “Validation Pyramid”

What it is

Who applies

Timelines

Evidence expectations

Conversion

2. MedTech and IVD: The Implants and Invasive Devices List

What it is

Who applies

Timelines

Evidence expectations

Conversion

3. Pharmaceuticals & Biotechnology—AmNOG-Style Pragmatism, Belgian Precision

What it is

Evidence expectations

Timelines

Conversion

4. Coding, Registries & Evidence Systems

Timelines & Planning Matrix — Belgium (2025)

Precision Pays — Strategic Planning for Belgium

Switzerland Lists, Lists, and Structured HTA

1) Devices & Appliances — MiGeL/LiMA (positive list)

2) Laboratory / IVD — Analysenliste (AL) under KLV

3) Pharma & Biotech Specialities List (SL/LS) + Art. 71 KVV bridge

4) Tariffs & Coding — SwissDRG/CHOP, TARMED → TARDOC (2026)

5) Digital & AI How they’re paid (no single “DiGA-style” list)

6) Private (Supplementary) Insurance — Where it helps (and where it doesn’t)

Timelines & Planning Matrix — Switzerland (2025)